View Filing Data

Print Document View Excel Document

Document and Entity Information - USD ($) $ in Millions	12 Months Ended
Document and Entity Information - USD ($) $ in Millions	Sep. 30, 2015	Dec. 01, 2015	Mar. 31, 2015
Document And Entity Information [Abstract]
Document Type	10-K
Amendment Flag	false
Document Period End Date	Sep. 30, 2015
Document Fiscal Year Focus	2015
Document Fiscal Period Focus	FY
Trading Symbol	SRDX
Entity Registrant Name	SURMODICS INC
Entity Central Index Key	0000924717
Current Fiscal Year End Date	--09-30
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Voluntary Filers	No
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		12,944,326
Entity Public Float			$ 245

Consolidated Balance Sheets - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Current Assets:
Cash and cash equivalents	$ 55,588	$ 43,511
Available-for-sale securities		3,040
Accounts receivable, net of allowance for doubtful accounts of $10 and $42 as of September 30, 2015 and 2014, respectively	7,478	4,751
Inventories	2,979	2,817
Deferred tax assets	546	394
Prepaids and other	1,198	751
Current assets of discontinued operations		16
Total Current Assets	67,789	55,280
Property and equipment, net	12,968	13,133
Available-for-sale securities		16,823
Deferred tax assets	6,704	6,718
Intangible assets, net	2,760	2,946
Goodwill	8,010	8,010
Other assets, net	479	1,979
Total Assets	98,710	104,889
Current Liabilities:
Accounts payable	781	1,028
Accrued liabilities:
Compensation	2,772	2,061
Accrued other	1,099	881
Deferred revenue	48	52
Current liabilities of discontinued operations		45
Total Current Liabilities	4,700	4,067
Deferred revenue, less current portion	217	226
Other long-term liabilities	1,920	1,845
Total Liabilities	6,837	6,138
Commitments and Contingencies (Note 12)
Stockholders’ Equity:
Series A preferred stock — $.05 par value, 450,000 shares authorized; no shares issued and outstanding
Common stock — $.05 par value, 45,000,000 shares authorized; 12,945,157 and 13,606,545 shares issued and outstanding, respectively	647	680
Additional paid-in capital	3,060	2,662
Accumulated other comprehensive income	5	1,528
Retained earnings	88,161	93,881
Total Stockholders’ Equity	91,873	98,751
Total Liabilities and Stockholders’ Equity	$ 98,710	$ 104,889

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 10	$ 42
Series A Preferred stock, par value	$ 0.05	$ 0.05
Series A Preferred stock, shares authorized	450,000	450,000
Series A Preferred stock, shares issued	0	0
Series A Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	45,000,000	45,000,000
Common stock, shares issued	12,945,157	13,606,545
Common stock, shares outstanding	12,945,157	13,606,545

Consolidated Statements of Income - USD ($) shares in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Revenue:
Royalties and license fees	$ 31,763,000	$ 30,277,000	$ 29,774,000
Product sales	24,925,000	22,798,000	22,506,000
Research and development	5,210,000	4,364,000	3,852,000
Total revenue	61,898,000	57,439,000	56,132,000
Operating costs and expenses:
Product costs	8,619,000	8,016,000	7,898,000
Research and development	16,165,000	15,550,000	15,079,000
Selling, general and administrative	15,525,000	15,297,000	13,859,000
Restructuring charges	0	0	476,000
Claim settlement	2,500,000
Total operating costs and expenses	42,809,000	38,863,000	37,312,000
Operating income from continuing operations	19,089,000	18,576,000	18,820,000
Other income (loss):
Investment income, net	156,000	238,000	268,000
Impairment losses on strategic investments	(1,500,000)	(1,184,000)	(158,000)
Gains on sale of strategic investments		709,000	1,293,000
Other income, net	496,000	133,000	137,000
Other (loss) income	(848,000)	(104,000)	1,540,000
Income from continuing operations before income taxes	18,241,000	18,472,000	20,360,000
Income tax provision	(6,294,000)	(6,265,000)	(5,781,000)
Income from continuing operations	11,947,000	12,207,000	14,579,000
Discontinued operations:
(Loss) income from discontinued operations, net of income taxes		(176,000)	588,000
(Loss) Income from discontinued operations		(176,000)	588,000
Net income	$ 11,947,000	$ 12,031,000	$ 15,167,000
Basic income (loss) per share:
Continuing operations	$ 0.92	$ 0.90	$ 1.01
Discontinued operations	0.00	(0.01)	0.04
Net income	0.92	0.88	1.05
Diluted income (loss) per share:
Continuing operations	0.90	0.88	0.99
Discontinued operations	0.00	(0.01)	0.04
Net income	$ 0.90	$ 0.87	$ 1.03
Weighted average number of shares outstanding:
Basic	13,029	13,632	14,464
Diluted	13,289	13,876	14,731

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Statement Of Income And Comprehensive Income [Abstract]
Net income	$ 11,947	$ 12,031	$ 15,167
Other comprehensive (loss) income, net of tax:
Unrealized holding (losses) gains on available-for-sale securities arising during the period	(1,208)	1,559	235
Reclassification adjustment for realized gains included in net income	(315)	(89)	(217)
Other comprehensive (loss) income	(1,523)	1,470	18
Comprehensive income	$ 10,424	$ 13,501	$ 15,185

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References + Details

Consolidated Statement of Shareholders' Equity - USD ($) $ in Thousands	Total	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Other Comprehensive Income [Member]	Retained Earnings [Member]
Beginning balance at Sep. 30, 2012	$ 94,988	$ 733	$ 18,346	$ 40	$ 75,869
Beginning balance, shares at Sep. 30, 2012		14,657,000
Net income	15,167				15,167
Other comprehensive income, net of tax	18			18
Issuance of common stock	275	$ 1	274
Issuance of common stock, shares		20,000
Common stock repurchased	$ (18,809)	$ (40)	(18,769)
Common stock repurchased, shares	(795,643)	(796,000)
Common stock options exercised, net	$ 144	$ 1	143
Common stock options exercised, net, shares	10,273	10,000
Purchase of common stock to pay employee taxes	$ (41)		(41)
Reduction or excess tax benefit from stock-based compensation plans	(477)		(477)
Stock-based compensation	2,552		2,552
Ending balance at Sep. 30, 2013	93,817	$ 695	2,028	58	91,036
Ending balance, shares at Sep. 30, 2013		13,891,000
Net income	12,031				12,031
Other comprehensive income, net of tax	1,470			1,470
Issuance of common stock	269	$ 8	261
Issuance of common stock, shares		163,000
Common stock repurchased	$ (11,541)	$ (25)	(2,330)		(9,186)
Common stock repurchased, shares	(485,777)	(485,000)
Common stock options exercised, net	$ 243	$ 2	241
Common stock options exercised, net, shares	190,434	38,000
Purchase of common stock to pay employee taxes	$ (1,111)		(1,111)
Reduction or excess tax benefit from stock-based compensation plans	236		236
Stock-based compensation	3,337		3,337
Ending balance at Sep. 30, 2014	98,751	$ 680	2,662	1,528	93,881
Ending balance, shares at Sep. 30, 2014		13,607,000
Net income	11,947				11,947
Other comprehensive income, net of tax	(1,523)			(1,523)
Issuance of common stock	279	$ 7	272
Issuance of common stock, shares		139,000
Common stock repurchased	(20,000)	$ (42)	(2,485)		(17,473)
Common stock repurchased, shares		(848,000)
Common stock options exercised, net	$ 431	$ 2	429
Common stock options exercised, net, shares	166,422	47,000
Purchase of common stock to pay employee taxes	$ (825)		(631)		(194)
Reduction or excess tax benefit from stock-based compensation plans	432		432
Stock-based compensation	2,381		2,381
Ending balance at Sep. 30, 2015	$ 91,873	$ 647	$ 3,060	$ 5	$ 88,161
Ending balance, shares at Sep. 30, 2015		12,945,000

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Operating Activities:
Net income	$ 11,947	$ 12,031	$ 15,167
Adjustments to reconcile net income to net cash provided by operating activities from continuing operations:
Loss (income) from discontinued operations		176	(588)
Depreciation and amortization	2,805	2,715	2,886
Gains on sales of available-for-sale securities, net and strategic investments	(492)	(842)	(1,430)
Impairment losses on strategic investments	1,500	1,184	158
Stock-based compensation	2,381	3,337	2,552
Deferred taxes	93	(352)	(492)
Excess tax (benefit) deficiency from stock-based compensation plans	(432)	(236)	477
(Gain) loss on disposals of property and equipment	(39)	2	(62)
Change in operating assets and liabilities, excluding the impact of discontinued operations:
Accounts receivable	(2,727)	581	(263)
Inventories	(162)	511	196
Prepaids and other	141	(23)	(40)
Accounts payable and accrued liabilities	373	(738)	238
Income taxes	(309)	116	(989)
Deferred revenue	(13)	75	(29)
Net cash provided by operating activities from continuing operations	15,066	18,537	17,781
Investing Activities:
Purchases of property and equipment	(1,877)	(2,278)	(1,919)
Cash proceeds from sale of property and equipment	42		77
Purchases of available-for-sale securities	(3,376)	(138,363)	(45,053)
Sales and maturities of available-for-sale securities	22,199	162,673	44,853
Business combination	(270)
Cash received from sale of strategic investments	21	709	2,236
Cash transferred to discontinued operations	(45)	(354)	(116)
Net cash provided by investing activities from continuing operations	16,694	22,387	78
Financing Activities:
Excess tax benefit (deficiency) from stock-based compensation plans	432	236	(477)
Issuance of common stock	710	512	419
Repurchase of common stock	(20,000)	(12,545)	(17,805)
Purchases of common stock to pay employee taxes	(825)	(1,111)	(41)
Net cash used in financing activities from continuing operations	(19,683)	(12,908)	(17,904)
Net cash provided by (used in) continuing operations	12,077	28,016	(45)
Discontinued Operations:
Net cash used in operating activities	(45)	(354)	(116)
Net cash provided by financing activities	45	354	116
Net change in cash and cash equivalents	12,077	28,016	(45)
Cash and Cash Equivalents:
Beginning of year	43,511	15,495	15,540
End of year	55,588	43,511	15,495
Supplemental Information:
Cash paid for income taxes	6,510	6,295	7,115
Noncash financing and investing activities:
Acquisition of property and equipment on account	22	11	26
Share repurchase accrual			$ 1,004
Issuance of performance shares, restricted and deferred stock units	2,250	$ 3,007
Accrual of business combination contingent consideration	$ 305

Schedule of Valuation and Qualifying Accounts

12 Months Ended

Sep. 30, 2015

Valuation And Qualifying Accounts [Abstract]

Schedule of Valuation and Qualifying Accounts

SurModics, Inc.

Valuation and Qualifying Accounts

(In thousands)

Description(1)	Balance at Beginning of Period		Additions Charged (Credited) to Expenses			Deductions From Reserves			Balance at End of Period
Year Ended September 30, 2013:
Allowance for doubtful accounts	$	40	$	(11	)	$	3	(a)	$	26
Restructuring accrual	$	192	$	476		$	252	(b)	$	416
Year Ended September 30, 2014:
Allowance for doubtful accounts	$	26	$	24		$	8	(a)	$	42
Restructuring accrual	$	416	$	—		$	416	(b)	$	—
Year Ended September 30, 2015:
Allowance for doubtful accounts	$	42	$	—		$	32	(a)	$	10
Restructuring accrual	$	—	$	—		$	—	(b)	$	—

(1)	Includes accounts associated with continuing operations.

(a)	Uncollectible accounts written off and adjustments to the allowance.

(b)	Adjustments to the accrual account reflect payments or non-cash charges associated with the accrual.

Description	12 Months Ended
Description	Sep. 30, 2015
Accounting Policies [Abstract]
Description	1. Description SurModics, Inc. and subsidiaries (“SurModics” or “the Company”) is a leading provider of medical device and in vitro diagnostic technologies to the healthcare industry. The Company derives its revenue from three primary sources: (1) royalties and license fees from licensing its proprietary drug delivery and surface modification technologies and in vitro diagnostic formats to customers; (2) the sale of reagent chemicals to licensees and the sale of stabilization products, antigens, substrates and surface coatings to the diagnostic and biomedical research markets; and (3) research and development fees generated on customer projects. Effective with the acquisition of Creagh Medical Ltd. (“Creagh”) on November 20, 2015, and subsequent to the fiscal year end 2015, the Company will be engaged in contract research and development, as well as manufacturing of balloon catheters used in a variety of interventional cardiology applications. Basis of Presentation The consolidated financial statements include all accounts and wholly-owned subsidiaries, and have been prepared in accordance with accounting principles generally accepted in the United States of America (“U.S.”) (“GAAP”). All inter-company transactions have been eliminated.

Summary of Significant Accounting Policies and Select Balance Sheet Information

12 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Summary of Significant Accounting Policies and Select Balance Sheet Information

2. Summary of Significant Accounting Policies and Select Balance Sheet Information

Cash and Cash Equivalents

Cash and cash equivalents consist of financial instruments with original maturities of three months or less and are stated at cost which approximates fair value and may include money market instruments, certificates of deposit, repurchase agreements and commercial paper instruments.

Investments

Investments consist principally of U.S. government and government agency obligations, mortgage-backed securities and corporate and municipal debt securities and were classified as available-for-sale at September 30, 2014. Available-for-sale securities are reported at fair value with unrealized gains and losses, net of tax, excluded from the consolidated statements of income and reported in the consolidated statements of comprehensive income as well as a separate component of stockholders’ equity in the consolidated balance sheets, except for other-than-temporary impairments, which are reported as a charge to current earnings. A loss would be recognized when there is an other-than-temporary impairment in the fair value of any individual security classified as available-for-sale, with the associated net unrealized loss reclassified out of accumulated other comprehensive income with a corresponding adjustment to other income (loss). This adjustment results in a new cost basis for the investment. Investments for which management has the intent and ability to hold to maturity are classified as held-to-maturity and reported at amortized cost. When an other-than-temporary impairment in the fair value of any individual security classified as held-to-maturity occurs, the Company writes down the security to fair value with a corresponding adjustment to other income (loss). Interest earned on debt securities, including amortization of premiums and accretion of discounts, is included in other income (loss). Realized gains and losses from the sales of debt securities, which are included in other income (loss), are determined using the specific identification method.

During the quarter ended June 30, 2015, the Company liquidated its investment portfolio to support corporate initiatives, as a result the ending balance of available-for-sale investments as of September 30, 2015 was zero. The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities as of September 30, 2014 were as follows (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
U.S. government and government agency obligations	$	7,397	$	12	$	(15	)	$	7,394
Mortgage-backed securities		5,576		43		(74	)		5,545
Municipal bonds		1,173		5		(3	)		1,175
Asset-backed securities		2,370		3		(4	)		2,369
Corporate bonds		1,829		6		(5	)		1,830
Equity securities		2		1,548		—			1,550
Total	$	18,347	$	1,617	$	(101	)	$	19,863

As of September 30, 2014, the Company concluded that the unrealized losses related to the available-for-sale securities shown above were not other-than-temporary as the Company did not have the intent to sell, nor was is it more likely than not that the Company would be required to sell such securities, before recovery of their amortized cost.

The following table summarizes sales of available-for-sale securities for the years ended September 30, 2015, 2014 and 2013 (in thousands):

	2015			2014			2013
Proceeds from sales	$	22,199		$	162,673		$	44,853
Gross realized gains	$	548		$	134		$	179
Gross realized losses	$	(73	)	$	(1	)	$	(43	)

There were no held-to-maturity debt securities at September 30, 2015 or 2014.

Inventories

Inventories are principally stated at the lower of cost or market using the specific identification method and include direct labor, materials and overhead. Inventories consisted of the following components as of September 30 (in thousands):

	2015		2014
Raw materials	$	1,264	$	1,056
Finished products		1,715		1,761
Total	$	2,979	$	2,817

Property and Equipment

Property and equipment are stated at cost, less any impairment, and are depreciated using the straight-line method over the estimated useful lives of the assets. The Company recorded depreciation expense of $2.0 million, $2.0 million and $2.1 million for the years ended September 30, 2015, 2014 and 2013, respectively.

The September 30, 2015 and 2014 balances in construction-in-progress include the cost of enhancing the capabilities of the Company’s Eden Prairie, Minnesota facility. As assets are placed in service, construction-in-progress is transferred to the specific property and equipment categories and depreciated over the estimated useful lives of the assets.

Property and equipment consisted of the following components as of September 30 (in thousands):

	Useful Life	2015			2014
	(In years)
Land	N/A	$	4,359		$	4,359
Laboratory fixtures and equipment	3 to 10		12,941			12,858
Buildings and improvements	3 to 20		16,444			16,114
Office furniture and equipment	3 to 10		3,473			3,060
Construction-in-progress			1,168			1,158
Less accumulated depreciation			(25,417	)		(24,416	)
Property and equipment, net		$	12,968		$	13,133

Other Assets

Other assets consisted principally of strategic investments as of September 30 as follows (in thousands):

	2015		2014
CeloNova BioSciences, Inc.	$	—	$	1,500
ViaCyte, Inc.		479		479
Other assets, net	$	479	$	1,979

In February 2011, the stent technology of Nexeon MedSystems, Inc. (“Nexeon”) was acquired by CeloNova BioSciences, Inc. (“CeloNova”). Prior to the acquisition by CeloNova, Nexeon created a wholly-owned subsidiary, Nexeon Stent, to hold the company’s stent-related assets. Nexeon distributed to its stockholders the Nexeon Stent stock which was exchanged for Series B-1 preferred shares of CeloNova. CeloNova is a privately-held Texas-based medical technology company that is marketing a variety of medical products. The Company’s investment in CeloNova, which is accounted for under the cost method, represents less than a 2% ownership interest. The Company does not exert significant influence over CeloNova’s operating or financial activities.

On November 10, 2015 Boston Scientific Corporation announced its intent to acquire CeloNova’s interventional radiology portfolio for $70 million plus potential milestone payments. This acquisition is expected to close by December 31, 2015. The Company recognized an other-than-temporary impairment loss of $1.5 million related to its investment in CeloNova in the fourth quarter fiscal 2015 based on the indicated value of this transaction.

The Company has invested a total of $1.2 million in ThermopeutiX, Inc. (“ThermopeutiX”), a California-based early stage company developing novel medical devices for the treatment of vascular and neurovascular diseases. In addition to the investment, SurModics has licensed its hydrophilic and hemocompatible coating technologies to ThermopeutiX for use with its devices. The Company’s investment in ThermopeutiX, which is accounted for under the cost method, represents an ownership interest of less than 20%. The Company does not exert significant influence over ThermopeutiX’s operating or financial activities. In the fourth quarter of fiscal 2014, the Company recognized an other-than-temporary impairment loss of $1.2 million based on capital funding initiatives and current operating conditions of ThermopeutiX.

The Company has invested a total of $5.3 million in ViaCyte, Inc. (“ViaCyte”), a privately-held California-based biotechnology firm that is developing a unique treatment for diabetes using coated islet cells, the cells that produce insulin in the human body. In fiscal 2006, the Company determined that its investment in ViaCyte was impaired and that the impairment was other-than-temporary. Accordingly, the Company recorded an impairment loss of $4.7 million. In the second quarter of fiscal 2013, the Company recorded an additional other-than-temporary impairment loss on this investment totaling $0.1 million based on a financing round and market valuations. The balance of the investment of $0.5 million, which is accounted for under the cost method, represents less than a 1% ownership interest. The Company does not exert significant influence over ViaCyte’s operating or financial activities.

The Company had invested a total of $2.5 million in Vessix Vascular, Inc. (“Vessix”) and recognized an other-than-temporary impairment loss on this investment totaling $2.4 million in fiscal 2010, based on market valuations and a pending financing round for Vessix. Vessix was purchased by Boston Scientific Corporation in November 2012. The Company recorded a gain of approximately $1.2 million in the consolidated statements of income gains on sale of strategic investments line, on the sale of this investment in the first quarter of fiscal 2013. In fiscal 2014, the Company recorded a $0.7 million gain upon achievement by Vessix of a clinical milestone and a sales milestone for calendar 2013. Total potential maximum additional proceeds of $3.3 million may be received in fiscal 2016 through fiscal 2017 depending on Vessix’s achievement of future sales milestones. No amounts have been recorded associated with these future milestones given the level of uncertainty that exists. Any potential additional income will be recognized once the milestones are achieved.

The Company transferred its original investment of $2,000 in Intersect ENT, Inc. (“Intersect ENT”) out of other assets to short-term available-for-sale investments upon completion of Intersect ENT’s initial public offering (“IPO”) in July 2014. The Company recognized a gain on this investment in other income of $0.5 million during the year ended September 30, 2015 as the investment was sold.

The Company has invested a total of $6.5 million in Nexeon, a privately-held West Virginia-based medical technology company, commencing in July 2007 and has recognized losses under the equity method of accounting as well as other-than-temporary impairment losses of $4.1 million in fiscal 2010 and less than $0.1 million in fiscal 2013. In the fourth quarter of fiscal 2013, the Company recognized an other-than-temporary impairment loss based on Nexeon’s capital funding initiatives of approximately $1.0 million. The carrying value of this investment was zero as of September 30, 2015 and 2014.

The total carrying value of cost method investments is reviewed quarterly for changes in circumstances or the occurrence of events that suggest the Company’s investment may not be recoverable. The fair value of cost method investments is not adjusted if there are no identified events or changes in circumstances that may have a material adverse effect on the fair value of the investment.

In the fiscal years ended September 30, 2015 and 2014, the Company recognized revenue of less than $0.1 million in each period and in the fiscal year ended September 30, 2013 the Company recognized revenue of $0.1 million from activity with companies in which it had a strategic investment.

Intangible Assets

Intangible assets consist principally of acquired patents and technology, customer relationships, licenses and trademarks. The Company recorded amortization expense of $0.8 million, $0.7 million and $0.7 million for the years ended September 30, 2015, 2014 and 2013, respectively. During the year ended September 30, 2015, the Company acquired certain assets from ImmunO4, LLC resulting in an increase in customer lists, non-compete and other intangible assets of $0.3 million, $0.2 million and $0.1 million, respectively.

Intangible assets consisted of the following as of September 30 (in thousands):

	2015
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists		9.0	$	5,132	$	(4,363	)	$	769
Core technology		8.0		530		(530	)		0
Non-compete		5.0		230		(12	)		218
Patents and other	16.8			2,321		(1,128	)		1,193
Subtotal				8,213		(6,033	)		2,180
Unamortized intangible assets:
Trademarks				580		—			580
Total			$	8,793	$	(6,033	)	$	2,760

	2014
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists		9.0	$	4,857	$	(3,813	)	$	1,044
Core technology		8.0		530		(475	)		55
Patents and other		16.8		2,256		(989	)		1,267
Subtotal				7,643		(5,277	)		2,366
Unamortized intangible assets:
Trademarks				580		—			580
Total			$	8,223	$	(5,277	)	$	2,946

Based on the intangible assets in service as of September 30, 2015, estimated amortization expense for each of the next five fiscal years is as follows (in thousands):

2016	$	690
2017		279
2018		233
2019		233
2020	221

Future amortization amounts presented above are estimates. Actual future amortization expense may be different, as a result of future acquisitions, impairments, changes in amortization periods, or other factors.

Goodwill

Goodwill represents the excess of the cost of an acquired entity over the fair value assigned to the assets purchased and liabilities assumed in connection with a company’s acquisition. Goodwill is not amortized but is subject, at a minimum, to annual tests for impairment in accordance with accounting guidance for goodwill. The carrying amount of goodwill is evaluated annually, and between annual evaluations if events occur or circumstances change indicating that it is more likely than not that the fair value of a reporting unit is less than its carrying amount.

Goodwill is evaluated for impairment based on an assessment of qualitative factors to determine whether the existence of events or circumstances leads to a determination that it is more likely than not that the fair value of a reporting unit is less than its carrying amount (Step 0). If, after assessing the totality of events or circumstances, an entity determines it is not more likely than not that the fair value of a reporting unit is less than its carrying amount, then performing the two-step impairment test becomes unnecessary.

The two-step impairment test requires SurModics to compare the fair value of the reporting units to which goodwill was assigned to their respective carrying values (Step 1 of the impairment test). In calculating fair value, the Company would use the income approach as its primary indicator of fair value, with the market approach used as a test of reasonableness. The income approach is a valuation technique under which the Company estimates future cash flows using the reporting units’ financial forecasts. Future estimated cash flows would be discounted to their present value to calculate fair value. The market approach establishes fair value by comparing SurModics to other publicly traded guideline companies or by analysis of actual transactions of similar businesses or assets sold. The income approach would be tailored to the circumstances of the Company’s business, and the market approach would be completed as a secondary test to ensure that the results of the income approach are reasonable and in line with comparable companies in the industry. The summation of the Company’s reporting units’ fair values would be compared and reconciled to its market capitalization as of the date of its impairment test.

In the situation where a reporting unit’s carrying amount exceeds its fair value, the amount of the impairment loss must be measured. The measurement of the impairment (Step 2 of the impairment test) is calculated by determining the implied fair value of a reporting unit’s goodwill. In calculating the implied fair value of goodwill, the fair value of the reporting unit is allocated to all other assets and liabilities of that unit based on their fair values. The excess of the fair value of a reporting unit over the amount assigned to its other assets and liabilities is the implied fair value of goodwill. The goodwill impairment is measured as the excess of the carrying amount of goodwill over its implied fair value.

The Company’s reporting units are the In Vitro Diagnostics operations known as its In Vitro Diagnostics unit which contains its BioFX branded products and the SurModics device drug delivery and hydrophilic coatings operations known as the Medical Device unit. Inherent in the determination of fair value of the reporting units are certain estimates and judgments, including the interpretation of current economic indicators and market valuations as well as the Company’s strategic plans with regard to its operations.

The $8.0 million of goodwill at September 30, 2015 and 2014 is related to the In Vitro Diagnostics reporting unit and represents the gross value from the acquisition of BioFX Laboratories, Inc. in 2007. The Company performed its annual impairment test of goodwill (Step 0) as of August 31, 2015, and did not record any goodwill impairment charges during fiscal 2015 as there were no indicators of impairment associated with the In Vitro Diagnostics reporting unit. The Company also did not record any goodwill impairment charges related to the In Vitro Diagnostics reporting unit during fiscal 2014 or 2013.

Valuation of Long-Lived Assets

Accounting guidance requires the Company to evaluate periodically whether events and circumstances have occurred that may affect the estimated useful life or the recoverability of the remaining balance of long-lived assets, such as property and equipment and intangibles with finite lives. If such events or circumstances were to indicate that the carrying amount of these assets may not be recoverable, the Company would estimate the future cash flows expected to result from the use of the assets and their eventual disposition. If the sum of the expected future cash flows (undiscounted and without interest charges) were less than the carrying amount of the assets, the Company would recognize an impairment charge to reduce such assets to their fair value.

Revenue Recognition

The Company recognizes revenue when all of the following criteria are met: (1) persuasive evidence of an arrangement exists; (2) shipment has occurred or delivery has occurred if the terms specify destination; (3) the sales price is fixed or determinable; and (4) collectability is reasonably assured. When there are additional performance requirements, revenue is recognized when all such requirements have been satisfied. Under revenue arrangements with multiple deliverables, the Company recognizes each separable deliverable as it is earned.

The Company derives its revenue from three primary sources: (1) royalties and license fees from licensing its proprietary drug delivery and surface modification technologies and in vitro diagnostic formats to customers; (2) the sale of reagent chemicals to licensees and the sale of stabilization products, antigens, substrates and surface coatings to the diagnostic and biomedical research markets; and (3) research and commercial development fees generated on customer projects.

Taxes collected from customers and remitted to governmental authorities are excluded from revenue and amounted to $0.1 million for each of the years ended September 30, 2015, 2014 and 2013.

Royalties and license fees. The Company licenses technology to third parties and collects royalties. Royalty revenue is generated when a customer sells products incorporating the Company’s licensed technologies. Royalty revenue is recognized as licensees report it to the Company, and payment is typically submitted concurrently with the report. For stand-alone license agreements, up-front license fees are recognized over the term of the related licensing agreement. Minimum royalty fees are recognized in the period earned.

Revenue related to a performance milestone is recognized upon the achievement of the milestone, as defined in the respective agreements and provided the following conditions have been met:

•

The milestone payment is non-refundable;

•

The milestone involved a significant degree of risk, and was not reasonably assured at the inception of the arrangement;

•

Accomplishment of the milestone involved substantial effort;

•

The amount of the milestone payment is commensurate with the related effort and risk; and

•

A reasonable amount of time passed between the initial license payment and the first and subsequent milestone payments.

If these conditions have not been met, the milestone payment is deferred and recognized over the term of the agreement.

Product sales. Product sales to third parties consist of direct and distributor sales and are recognized at the time of shipment. The Company’s sales terms provide no right of return outside of the standard warranty policy. Payment terms are generally set at 30-45 days.

Research and development. The Company performs third-party research and development activities, which are typically provided on a time and materials basis. Generally, revenue for research and development is recorded as performance progresses under the applicable contract.

Arrangements with multiple deliverables. Revenue arrangements with multiple deliverables requires the Company to:

(i) disclose whether multiple deliverables exist, how the deliverables in an arrangement should be separated, and how the consideration should be allocated;

(ii) allocate revenue in an arrangement using estimated selling prices (“ESP”) of deliverables if a vendor does not have vendor-specific objective evidence of selling price (“VSOE”) or third-party evidence of selling price (“TPE”); and

(iii) allocate revenue using the relative selling price method.

The Company accounts for revenue using a multiple attribution model in which consideration allocated to research and development activities is recognized as performed, and milestone payments are recognized when the milestone events are achieved, when such activities and milestones are deemed substantive. Accordingly, in situations where a unit of accounting includes both a license and research and development activities, and when a license does not have stand-alone value, the Company applies a multiple attribution model in which consideration allocated to the license is recognized ratably, consideration allocated to research and development activities is recognized as performed and milestone payments are recognized when the milestone events are achieved, when such activities and milestones are deemed substantive.

The Company enters into license and development arrangements that may consist of multiple deliverables which could include a license(s) to SurModics’ technology, research and development activities, manufacturing services, and product sales based on the needs of its customers. For example, a customer may enter into an arrangement to obtain a license to SurModics’ intellectual property which may also include research and development activities, and supply of products manufactured by SurModics. For these services provided, SurModics could receive upfront license fees upon signing of an agreement and granting the license, fees for research and development activities as such activities are performed, milestone payments contingent upon advancement of the product through development and clinical stages to successful commercialization, fees for manufacturing services and supply of product, and royalty payments based on customer sales of product incorporating SurModics’ technology. The Company’s license and development arrangements generally do not have refund provisions if the customer cancels or terminates the agreement. Typically all payments made are non-refundable.

The Company is required to evaluate each deliverable in a multiple element arrangement for separability. The Company is then required to allocate revenue to each separate deliverable using a hierarchy of VSOE, TPE, or ESP. In many instances, the Company is not able to establish VSOE for all deliverables in an arrangement with multiple elements. This may be a result of the Company infrequently selling each element separately or having a limited history with multiple element arrangements. When VSOE cannot be established, the Company attempts to establish a selling price of each element based on TPE. TPE is determined based on competitor prices for similar deliverables when sold separately.

When the Company is unable to establish a selling price using VSOE or TPE, the Company uses ESP in its allocation of arrangement consideration. The objective of ESP is to determine the price at which the Company would transact a sale if the product or service were sold on a stand-alone basis. ESP is generally used for highly customized offerings.

The Company determines ESP for undelivered elements by considering multiple factors including, but not limited to, market conditions, competitive landscape and past pricing arrangements with similar features. The determination of ESP is made through consultation with the Company’s management, taking into consideration the marketing strategies for each business unit.

Deferred Revenue

Amounts received prior to satisfying the above revenue recognition criteria are recorded as deferred revenue in the accompanying consolidated balance sheets, with deferred revenue to be recognized beyond one year being classified as non-current deferred revenue. The Company had deferred revenue of $0.3 million for September 30, 2015 and 2014.

Customer advances are accounted for as a liability until all criteria for revenue recognition have been met.

Customer Concentrations

The Company’s licensed technologies provide royalty revenue, which represents the largest revenue stream to the Company. The Company has licenses with a diverse base of customers and certain customers have multiple products using the Company’s technology. Medtronic plc (“Medtronic”) is the Company’s largest customer at 26% of total revenue for fiscal 2015. Medtronic has several separately licensed products that generate royalty revenue for SurModics, none of which represented more than 6% of SurModics’ total revenue. No other individual customer using licensed technology constitutes more than 10% of the Company’s total revenue.

The Company’s licensing agreements with many of its customers, including most of its significant customers, cover many licensed products that each separately generates royalty revenue. This structure reduces the potential risk to the Company’s operations that may result from reduced sales (or the termination of a license) of a single product for any specific customer.

Research and Development

Research and development costs are expensed as incurred. Some research and development costs are related to third-party contracts, and the related revenue is recognized as described in “Revenue Recognition” above. Costs associated with customer-related research and development include specific project direct labor costs and material expenses as well as an allocation of overhead costs based on direct labor dollars.

Use of Estimates

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenue and expenses during the reporting period. Ultimate results could differ from those estimates.

Income Per Share Data

Basic income per common share is calculated based on the weighted average number of common shares outstanding during the period. Diluted income per common share is computed by dividing income by the weighted average number of common and common equivalent shares outstanding during the period. The Company’s only potentially dilutive common shares are those that result from dilutive common stock options and non-vested stock relating to restricted stock awards, restricted stock units and performance shares.

The following table sets forth the denominator for the computation of basic and diluted income per share (in thousands):

	2015		2014		2013
Net income from continuing operations available to common shareholders	$	11,947	$	12,207	$	14,579

Basic weighted average shares outstanding		13,029		13,632		14,464
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units and performance shares		260		244		267
Diluted weighted average shares outstanding		13,289		13,876		14,731

The calculation of weighted average diluted shares outstanding excludes outstanding common stock options associated with the right to purchase 0.5 million, 0.5 million and 0.4 million shares for fiscal 2015, 2014 and 2013, respectively, as their inclusion would have had an antidilutive effect on diluted income per share.

New Accounting Pronouncements

Accounting Standards to be Adopted

In July 2013, the Financial Accounting Standards Board (“FASB”) issued amended guidance on the financial statement presentation of an unrecognized tax benefit when a net operating loss carryforward exists, similar to a tax loss, or tax credit carryforward. The guidance requires an unrecognized tax benefit, or a portion of an unrecognized tax benefit, be presented as a reduction of a deferred tax asset when a net operating loss carryforward exists, or similar tax loss, or tax credit carryforward, with certain exceptions. This accounting guidance was adopted during the first quarter of fiscal 2015. The adoption did not have a material impact on the Company’s financial position, results of operation or cash flows.

In May 2014, the FASB issued new revenue recognition guidance for recognizing revenue from contracts with customers that provides a five-step analysis of transactions to determine when and how revenue is recognized. The guidance states that a Company should recognize revenue which depicts the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to receive in exchange for those goods or services. The new standard will also result in enhanced disclosures about revenue related to the nature, amount, timing, and uncertainty of revenue and cash flows arising from contracts with customers. The standard also requires quantitative and qualitative disclosures about customer contracts, significant judgments and changes in judgments, and assets recognized from the costs to obtain or fulfill a contract. Additionally, the FASB has provided guidance for transactions that were not previously addressed comprehensively, and improved guidance for multiple-element arrangements. The original pronouncement was effective for the Company beginning in fiscal 2018 (October 1, 2017), and early adoption was not permitted. On July 9, 2015 the FASB approved a one-year deferral of the effective date for the revenue recognition standard. As a result of the one-year deferral, the revenue recognition standard is effective for the Company beginning in fiscal 2019 (October 1, 2018), however, the Company may adopt this guidance as of the original effective date. This guidance can be adopted by the Company either retrospectively (October 1, 2016) or as a cumulative-effect adjustment as of the date of adoption. The Company is currently evaluating the impact that the adoption of this new accounting guidance will have on the Company’s results of operations, cash flows and financial position.

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s consolidated financial statements..

Discontinued Operations

12 Months Ended

Sep. 30, 2015

Discontinued Operations And Disposal Groups [Abstract]

Discontinued Operations

3. Discontinued Operations

On November 1, 2011, the Company entered into a definitive agreement (the “Purchase Agreement”) to sell substantially all of the assets of its wholly-owned subsidiary, SurModics Pharmaceuticals, to Evonik Degussa Corporation (“Evonik”). Under the terms of the Purchase Agreement, the entire portfolio of products and services of SurModics Pharmaceuticals, including the Company’s Current Good Manufacturing Practices (“cGMP”) development and manufacturing facility located in Birmingham, Alabama, were sold. The Company retained all accounts receivable and the majority of liabilities associated with SurModics Pharmaceuticals incurred prior to closing. The sale (the “Pharma Sale”) closed on November 17, 2011. The total consideration received from the Pharma Sale was $30.0 million in cash. As part of the Pharma Sale, SurModics agreed not to compete in the restricted business (as defined in the Purchase Agreement) for a period of five years and to indemnify Evonik against specified losses in connection with SurModics Pharmaceuticals, including certain contingent consideration obligations related to the acquisition by SurModics Pharmaceuticals of the portfolio of intellectual property and drug delivery projects from PR Pharmaceuticals, Inc. (“PR Pharma”) and other specified excluded liabilities, including the litigation matter with Southern Research Institute (“SRI”) described below. SurModics retained responsibility for repayment obligations related to an agreement with various governmental authorities associated with creation of jobs in Alabama. These repayment obligations were settled or terminated in the second and third quarters of fiscal 2013 with payments totaling $325,000 repaid to the governmental authorities and a gain of $1.3 million recognized in the fiscal year ended September 30, 2013.

The following is a summary of the operating results of SurModics Pharmaceuticals discontinued operations for the years ended September 30 (in thousands):

	2014			2013
Total revenue	$	—		$	—

(Loss) income from discontinued operations	$	(260	)	$	1,136
Income tax benefit (provision)		84			(548	)
(Loss) income from discontinued operations, net of income taxes	$	(176	)	$	588
Loss on sale of discontinued operations	$	—		$	—
Income tax benefit		—			—
Loss on sale of discontinued operations, net of income Taxes	$	—		$	—

The assets and liabilities of discontinued operations as of September 30 were immaterial to the consolidated financial statements.

In June 2014, the Company resolved the previously disclosed litigation involving SRI, two of SRI’s former employees and SurModics Pharmaceuticals. Additionally, in September 2014, the Company reached a final settlement with a second inventor, one of SRI’s former employees, of the technology subject to the SRI litigation matter. In connection with the resolution of the litigation, the Company recorded an additional expense, within discontinued operations, of $0.3 million during fiscal 2014. Additionally, in the fourth quarter of fiscal 2014, SurModics submitted a bid of less than $0.1 million related to our indemnification obligations to Evonik related to a contingent consideration matter associated with the PR Pharma intellectual property purchased by Evonik in the Pharma Sale. SurModics was notified in October 2014 that the bid was accepted and made a payment made at that time. The assets and liabilities of discontinued operations as of September 30, 2014 include the amount associated with the bid for the legal rights.

- Definition

The entire disclosure related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

+ Details

Fair Value Measurements

12 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Fair Value Measurements

4. Fair Value Measurements

The accounting guidance on fair value measurements defines fair value, establishes a framework for measuring fair value under U.S. GAAP, and expands disclosures about fair value measurements. The guidance is applicable for all financial assets and financial liabilities and for all nonfinancial assets and nonfinancial liabilities recognized or disclosed at fair value in the consolidated financial statements on a recurring basis. Fair value is defined as the exchange price that would be received from selling an asset or paid to transfer a liability (an exit price) in an orderly transaction between market participants at the measurement date. When determining the fair value measurements for assets and liabilities required or permitted to be recorded at fair value, the Company considers the principal or most advantageous market in which it would transact and also considers assumptions that market participants would use when pricing the asset or liability, such as inherent risk, transfer restrictions and risk of nonperformance.

Fair Value Hierarchy

Accounting guidance on fair value measurements requires that assets and liabilities carried at fair value be classified and disclosed in one of the following three categories:

Level 1 — Quoted (unadjusted) prices in active markets for identical assets or liabilities.

The Company’s Level 1 assets as of September 30, 2014 consisted of its investment in Intersect ENT and certain U.S. government and government agency obligations. The fair market value of the Intersect ENT investment was based on the quoted price of Intersect ENT shares as traded on the NASDAQ Global Market Stock Exchange. This investment was sold in the second quarter of fiscal 2015 generating a realized gain of $0.5 million. The fair market value of certain U.S. government and government agency obligations were based on observable prices in highly active treasury and agency security markets for identical securities.

Level 2 — Observable inputs other than quoted prices included in Level 1, such as quoted prices for similar assets or liabilities in active markets; quoted prices for identical or similar assets or liabilities in markets that are not active; or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the asset or liability.

The Company’s Level 2 assets as of September 30, 2015 consisted of money market funds and commercial paper instruments. For the year ended September 30, 2014 the Company’s Level 2 assets consisted of money market funds, commercial paper instruments, U.S. Treasury securities, corporate bonds, municipal bonds, U.S. government agency securities, government agency and municipal securities and certain asset-backed and mortgage-backed securities. Fair market values for these assets are based on quoted vendor prices and broker pricing where all significant inputs are observable. The Company performs limited tests of the quoted vendor prices based on available U.S. Treasury security pricing on government websites as a means of validating the third party pricing. To ensure the accuracy of quoted vendor prices and broker pricing, the Company performs regular reviews of investment returns to industry benchmarks and sample tests of individual securities to validate quoted vendor prices with other available market data.

Level 3 — Unobservable inputs to the valuation methodology that are supported by little or no market activity and that are significant to the measurement of the fair value of the assets or liabilities. Level 3 assets and liabilities include those whose fair value measurements are determined using pricing models, discounted cash flow methodologies or similar valuation techniques, as well as significant management judgment or estimation.

There were no Level 3 assets at September 30, 2015 or 2014 and there was no Level 3 activity during fiscal 2015.

In valuing assets and liabilities, the Company is required to maximize the use of quoted market prices and minimize the use of unobservable inputs. The Company did not significantly change its valuation techniques from prior periods.

Assets and Liabilities Measured at Fair Value on a Recurring Basis

In instances where the inputs used to measure fair value fall into different levels of the fair value hierarchy, the fair value measurement has been determined based on the lowest level input that is significant to the fair value measurement in its entirety. The Company’s assessment of the significance of a particular item to the fair value measurement in its entirety requires judgment, including the consideration of inputs specific to the asset or liability. During the year ended September 30, 2015, the Company liquidated all of its available-for-sale debt and equity securities and is invested solely in cash equivalents as of September 30, 2015. The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2015 (in thousands):

	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value as of September 30, 2015
Assets:
Cash equivalents	$	—	$	53,591	$	—	$	53,591
Total assets measured at fair value	$	—	$	53,591	$	—	$	53,591

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2014 (in thousands):

	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value as of September 30, 2014
Assets:
Cash equivalents	$	—	$	40,100	$	—	$	40,100
Available-for-sale equity securities		1,550		—		—		1,550
Available-for-sale debt securities:
U.S. government and government agency obligations		—		7,394		—		7,394
Mortgage-backed securities		—		5,545		—		5,545
Municipal bonds		—		1,175		—		1,175
Asset-backed securities		—		2,369		—		2,369
Corporate bonds		—		1,830		—		1,830
Total assets measured at fair value	$	1,550	$	58,413	$	—	$	59,963

Valuation Techniques

The valuation techniques used to measure the fair value of assets are as follows:

Cash equivalents — These assets are classified as Level 2 and are carried at historical cost which is a reasonable estimate of fair value because of the relatively short time between origination of the instrument and its expected realization.

Available-for-sale equity securities – This asset is classified as Level 1 and represents the Company’s investment in Intersect ENT. This investment was valued based on the quoted market price of Intersect ENT shares.

Available-for-sale debt securities — These securities are classified as Level 2 and include various types of debt securities. These securities are valued based on quoted vendor prices in active markets underlying the securities.

Assets and Liabilities Measured at Fair Value on a Non-Recurring Basis

The Company’s investments in non-marketable securities of private companies are accounted for using the cost method as the Company does not exert significant influence over the investees’ operating or financial activities. These investments are measured at fair value on a non-recurring basis when they are deemed to be other-than-temporarily impaired. In determining whether a decline in value of non-marketable equity investments in private companies has occurred and is other-than-temporary, an assessment is made by considering available evidence, including the general market conditions in the investee’s industry, the investee’s product development status and subsequent rounds of financing and the related valuation and/or the Company’s participation in such financings. The Company also assesses the investee’s ability to meet business milestones and the financial condition and near-term prospects of the individual investee, including the rate at which the investee is using its cash and the investee’s need for possible additional funding at a potentially lower valuation. The valuation methodology for determining the decline in value of non-marketable equity securities is based on inputs that require management judgment and are Level 3 inputs.

In the fourth quarter of fiscal 2015, the Company recognized an other-than-temporary impairment loss of $1.5 million based on the indicated value of a third-party transaction expected to close by December 31, 2015. See Note 2 for further information.

In the fourth quarter of fiscal 2014, the Company recognized an other-than-temporary impairment loss of $1.2 million based on capital funding initiatives and current operating conditions of ThermopeutiX. See Note 2 for further information.

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

Stockholders' Equity	12 Months Ended
Stockholders' Equity	Sep. 30, 2015
Equity [Abstract]
Stockholders' Equity	5. Stockholders’ Equity Repurchase of Common Stock Shares are repurchased from time to time to support the Company’s stock-based compensation programs and to return capital to stockholders. The Company accounts for repurchases of common stock using the par value method. On January 28, 2013, the Company’s Board of Directors authorized the repurchase of up to an additional $10.0 million of the Company’s outstanding common stock. As of June 30, 2013, the Company had completed the January 2013 authorization as well as the remaining $0.3 million under a previous authorization as the Company repurchased a cumulative 405,290 shares at an average price of $25.47 per share. On July 29, 2013, the Company’s Board of Directors authorized the repurchase of up to an additional $20.0 million of the Company’s outstanding common stock through open-market purchases, private transactions, block trades, accelerated share repurchase transactions, tender offers, or by any combination of such methods. Through September 30, 2013, the Company had repurchased 390,353 shares at an average price of $21.71 under the July 2013 authorization. The Company had $11.5 million available for future share repurchases as of September 30, 2013. During fiscal 2014, the Company repurchased an aggregate of 485,777 shares of common stock for a total of $11.5 million under the July 2013 authorization at an average price of $23.77 per share. The July 2013 authorized amount was used as of September 30, 2014 with a small amount remaining. During fiscal 2013, the Company repurchased an aggregate of 795,643 shares of common stock for a total of $18.8 million under the May 2012, January 2013 and July 2013 authorizations, including $1.0 million associated with open market repurchases at September 30, 2013. On November 5, 2014, the Company’s Board of Directors authorized it to repurchase up to $30.0 million of the Company’s outstanding common stock in open-market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, tender offers or by any combination of such methods. The authorization has no fixed expiration date. As part of the accelerated share repurchase (“ASR”) program discussed below, the Company repurchased 758,143 shares of common stock on November 11, 2014 and 89,721 of common stock on July 8, 2015, the date that the ASR program was completed. As adjusted for the final ASR program settlement, $10.0 million remained available for future repurchases under the November 5, 2014 authorization. On November 11, 2014, the Company entered into an accelerated share repurchase program with Wells Fargo Bank, National Association. In connection with this agreement, the Company made a $20.0 million payment to the bank and immediately received an initial delivery of 758,143 shares of its common stock with a fair value of $16.0 million as of the purchase date. Effective as of the date of the initial share purchase, the transaction was accounted for as a share retirement, resulting in a reduction of common stock of less than $0.1 million, additional paid-in capital of $2.5 million and retained earnings of $13.5 million. The remaining $4.0 million of the Company’s payment was also reported as a reduction in retained earnings. The specific number of shares that the Company ultimately purchased under the ASR agreement was based on the volume weighted average price of the Company’s common stock during the purchase period, less an agreed upon discount. In the aggregate the Company purchased 847,864 shares under the ASR program for an average price of $23.59 per share. Based on the facts associated with the agreement, the forward contract was indexed to the Company’s common stock and met the U.S. GAAP requirements to be classified as permanent equity as of July 8, 2015. On November 6, 2015, the Company’s Board of Directors authorized the repurchase of up to $20.0 million of the Company’s outstanding common stock in addition to the $10.0 million authorization which remains available from the November 5, 2014 authorization.

- Definition

The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(d),(e))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 4
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21484-112644

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB TOPIC 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21488-112644

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 4
-Subparagraph (SAB TOPIC 4.C)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187143-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 6
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21506-112644

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 30
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6405834&loc=d3e23285-112656

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21475-112644

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Preferred Stock
-URI http://asc.fasb.org/extlink&oid=6521494

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21463-112644

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=6928386&loc=d3e21564-112644

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section E

Reference 15: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Staff Accounting Bulletin (SAB)
-Number Topic 4
-Section C

+ Details

Stock-Based Compensation Plans

12 Months Ended

Sep. 30, 2015

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Plans

6. Stock-Based Compensation Plans

The Company has stock-based compensation plans under which it grants stock options, restricted stock awards, performance share awards, restricted stock units and deferred stock units. Accounting guidance requires all share-based payments to be recognized as an operating expense, based on their fair values, over the requisite service period. The Company’s stock-based compensation expenses for the years ended September 30 were allocated to the following expense categories (in thousands):

	2015		2014		2013
Product costs	$	24	$	16	$	22
Research and development		226		175		180
Selling, general and administrative		2,131		3,146		2,350
Total stock-based compensation expense	$	2,381	$	3,337	$	2,552

As of September 30, 2015, approximately $1.9 million of total unrecognized compensation costs related to non-vested awards is expected to be recognized over a weighted average period of approximately 2.1 years. Such costs include $0.2 million based on payout levels associated with performance share awards that are currently anticipated to be fully expensed because the performance conditions are expected to be met above the minimum levels for each award period.

Stock Option Awards

The Company uses the Black-Scholes option pricing model to determine the weighted average grant date fair value of stock options. Weighted average per share fair values of stock options granted during fiscal 2015, 2014 and 2013 were $7.26, $8.72 and $8.69, respectively. The assumptions used as inputs in the model for the years ended September 30 were as follows:

	2015			2014			2013
Risk-free interest rates		1.43	%		1.19	%		0.60	%
Expected life	4.5 years			4.6 years			4.8 years
Expected volatility		43	%		45	%		49	%
Dividend yield		0	%		0	%		0	%

The risk-free interest rate assumption was based on the U.S. Treasury’s rates for U.S. Treasury zero-coupon bonds with maturities similar to those of the expected term of the award. The expected life of options granted is determined based on the Company’s experience. Expected volatility is based on the Company’s stock price movement over a period approximating the expected term. Based on management’s judgment, dividend rates are expected to be zero for the expected life of the options. The Company also estimates forfeitures of options granted, which are based on historical experience.

Non-qualified stock options are granted at fair market value on the grant date. Non-qualified stock options expire in seven to ten years or upon termination of employment or service as a Board member. With respect to members of our Board, non-qualified stock options generally become exercisable on a pro-rata basis over the one-year period following the date of grant. With respect to our employees, non-qualified stock options generally become exercisable with respect to 25% of the shares on each of the first four anniversaries following the grant date.

Non-qualified stock options granted prior to May 2008 generally become exercisable with respect to 20% of the shares on each of the first five anniversaries following the grant date, and non-qualified stock options granted to the Company’s employees subsequent to April 2008 generally become exercisable with respect to 25% of the shares on each of the first four anniversaries following the grant date.

The Company modified non-qualified stock option awards granted to Board members in February 2014, which resulted in acceleration of the stock option vesting period. The modification changed the vesting period to a pro-rata basis over a one-year period from a four-year period and resulted in an increase to stock option expense of $0.5 million in fiscal 2014.

Shareholders approved the 2009 Equity Incentive Plan (“2009 Plan”) at the February 8, 2010 Annual Meeting of Shareholders. The 2009 Plan has 1,500,000 shares authorized, plus the number of shares that have not yet been awarded under the 2003 Equity Incentive Plan, or were awarded and subsequently returned to the pool of available shares under the 2003 Equity Incentive Plan pursuant to its terms. At September 30, 2015, there were 938,391 shares available for future awards. As of September 30, 2015, the aggregate intrinsic value of the option shares outstanding and option shares exercisable was $4.5 million and $3.8 million, respectively. At September 30, 2015, the average remaining contractual life of options outstanding and options exercisable was 3.2 and 2.4 years, respectively. The total pre-tax intrinsic value of options exercised during fiscal 2015 and 2014 was $1.7 million and $1.4 million, respectively. The intrinsic value represents the difference between the exercise price and the fair market value of the Company’s common stock on the last day of the respective fiscal period end.

The following table summarizes all stock options activity and stock options outstanding and exercisable under the stock option plans during fiscal 2015, 2014 and 2013:

	Number of Shares			Weighted Average Exercise Price
Outstanding at September 30, 2012		1,325,438		$	21.25
Granted		178,924			20.85
Exercised		(10,273	)		14.40
Forfeited		(125,105	)		33.47
Outstanding at September 30, 2013		1,368,984			20.13
Granted		138,837			22.71
Exercised		(190,434	)		14.42
Forfeited		(106,768	)		31.26
Outstanding at September 30, 2014		1,210,619			20.35
Granted		164,401			21.24
Exercised		(166,422	)		14.54
Forfeited		(90,590	)		35.35
Outstanding at September 30, 2015		1,118,008			20.10
Exercisable at September 30, 2015		797,045		$	20.04

The stock-based compensation table includes stock options activity related to discontinued operations, however, there were no stock options outstanding or exercisable related to discontinued operations as of September 30, 2015, 2014 or 2013.

Restricted Stock Awards

The Company has entered into restricted stock agreements with certain key employees, covering the issuance of common stock (“Restricted Stock”). Under accounting guidance, these shares are considered to be non-vested shares. The Restricted Stock is released to the key employees if they are employed by the Company at the end of the vesting period. Compensation has been recognized for the estimated fair value of the common shares and is being charged to income over the vesting term. The stock-based compensation table above includes Restricted Stock expenses recognized related to these awards, which totaled $0.3 million, $0.2 million and $0.1 million during fiscal 2015, 2014 and 2013, respectively.

The following table summarizes all restricted stock awards activity during fiscal 2015, 2014 and 2013:

	Number of Shares			Weighted Average Grant Price
Balance at September 30, 2012		4,000		$	22.11
Vested		5,234			23.88
Forfeited		(4,000	)		22.11
Balance at September 30, 2013		5,234			23.88
Granted		22,155			22.67
Vested		(7,991	)		23.98
Forfeited		(774	)		22.58
Balance at September 30, 2014		18,624			22.45
Granted		18,073			21.84
Vested		(7,606	)		22.28
Forfeited		(1,316	)		22.16
Balance at September 30, 2015		27,775		$	22.12

The stock-based compensation table includes restricted stock awards activity related to discontinued operations, however, there were no restricted stock awards outstanding related to discontinued operations as of September 30, 2015, 2014 or 2013.

Performance Share Awards

The Company has entered into performance share agreements with certain key employees, covering the issuance of common stock (“Performance Shares”). The Performance Shares vest upon the achievement of all or a portion of certain performance objectives, which must be achieved during the performance period. The Performance Shares are not issued and outstanding until the performance objectives are met. Performance objectives selected by the Organization and Compensation Committee of the Board of Directors (the “Committee”) were cumulative earnings per share and cumulative revenue for the three-year performance periods for fiscal 2012 (2012 – 2014), fiscal 2013 (2013 – 2015), fiscal 2014 (2014 – 2016) and fiscal 2015 (2015 – 2017). Assuming that the minimum performance level is attained, the number of shares that may actually vest will vary based on performance from 20% (minimum) to 200% (maximum). Shares will be issued to participants as soon as practicable following the end of the performance periods subject to Committee approval and verification of results. The compensation cost related to the number of shares to be granted under each performance period is fixed on the grant date, which is the date the performance period begins. Compensation expense is recognized in each period based on management’s best estimate of the achievement level of the specified performance objectives for Performance Shares. In fiscal 2015, the Company recognized expense of $0.5 million related to probable achievement of performance objectives for three-year Performance Shares granted in fiscal 2015, 2014 and 2013. In fiscal 2014, the Company recognized expense of $0.6 million related to probable achievement of performance objectives for three-year Performance Shares granted in fiscal 2014, 2013 and 2012. In fiscal 2013, the Company recognized expense of $1.2 million related to probable achievement of performance objectives for three-year Performance Shares granted in fiscal 2012 and 2011. The stock-based compensation table above includes the Performance Shares expenses.

The fair values of the Performance Shares, at target, were $0.9 million, $0.9 million and $0.9 million for grants awarded in fiscal 2015, 2014 and 2013, respectively.

The aggregate number of shares that could be awarded to key employees if the minimum, target and maximum performance goals are met, based upon the fair value at the date of grant is as follows:

Performance Period	Minimum Shares		Target Shares		Maximum Shares
Fiscal 2013 – 2015		8,551		42,753		85,506
Fiscal 2014 - 2016		7,861		39,303		78,606
Fiscal 2015 – 2017		8,440		42,199		84,398

The Fiscal 2013 – 2015 awards are expected to be finalized in December 2015 at an estimated 41,727 shares based on performance objective results. Based on the Company’s performance through September 30, 2015, it is estimated that approximately 3,930 shares may be earned for the Fiscal 2014 – 2016 performance period and that approximately 10,676 shares may be earned for the Fiscal 2015 – 2017 performance period.

1999 Employee Stock Purchase Plan

Under the 1999 Employee Stock Purchase Plan (“Stock Purchase Plan”), the Company is authorized to issue up to 400,000 shares of common stock. All full-time and part-time employees can choose to have up to 10% of their annual compensation withheld, with a limit of $25,000, to purchase the Company’s common stock at purchase prices defined within the provisions of the Stock Purchase Plan. As of September 30, 2015 and 2014, there were less than $0.1 million of employee contributions in each period included in accrued liabilities in the consolidated balance sheets. Stock compensation expense recognized related to the Stock Purchase Plan totaled $0.1 million, $0.1 million and $0.1 million, during fiscal 2015, 2014 and 2013, respectively. The stock-based compensation table above includes the Stock Purchase Plan expenses.

Restricted Stock and Deferred Stock Units

The Company has awarded a total of 23,736 restricted stock units (“RSU”) in fiscal 2015 and 2014 under the 2009 Equity Incentive Plan to non-employee directors with forfeiture of 3,068 RSUs in fiscal 2015. The Company modified the RSU awards granted to Board members in February 2014, which resulted in acceleration of the RSU award vesting period. The modification changed the vesting period to a pro-rata basis over a one-year period from a three-year period and resulted in an increase to RSU award expense of $0.2 million in fiscal 2014. RSU awards are not considered issued or outstanding common stock of the Company until they vest. The estimated fair value of the RSU awards was calculated based on the closing market price of SurModics’ common stock on the date of grant. Compensation expense has been recognized for the estimated fair value of the common shares and is being charged to income over the vesting term. The stock-based compensation table above includes RSU expenses recognized related to these awards, which totaled $0.2 million, $0.4 million and $0.1 million for fiscal 2015, 2014 and 2013, respectively.

Directors can also elect to receive their annual fees for services to the Board in deferred stock units (“DSUs”). Certain directors elected this option beginning on January 1, 2013 which has resulted in 18,934 units issued with a total value of $0.4 million. These DSUs are fully vested. Stock-based compensation expense related to DSU awards, totaled $0.1 million in both fiscal 2015 and 2014.

Restructuring Charges

12 Months Ended

Sep. 30, 2015

Restructuring And Related Activities [Abstract]

Restructuring Charges

7. Restructuring Charges

During the fiscal years ended September 30, 2015 and 2014, the Company did not incur any restructuring charges. The restructuring charge for fiscal 2013 described below has been presented separately as restructuring charges in the consolidated statements of income.

In September 2013 (fiscal 2013), the Company announced a realignment of its business to enhance focus on key growth initiatives. As a result of the organizational change, the Company eliminated approximately 6% of its workforce. These employee terminations occurred across various functions, and the reorganization plan was completed by the end of fiscal 2013. The Company recorded total pre-tax restructuring charges of $0.5 million in the fourth quarter of fiscal 2013, which consisted of severance pay and benefits expenses.

The following table summarizes the restructuring accrual activity (in thousands):

	Employee Severance and Benefits			Facility- Related Costs			Total
Balance at September 30, 2012	$	10		$	182		$	192
Accrual/(reversal) during the year		534			(58	)		476
Cash payments		(145	)		(107	)		(252	)
Balance at September 30, 2013	$	399		$	17		$	416
Accrual/(reversal) during the year		(20	)		(2	)		(22	)
Cash payments		(379	)		(15	)		(394	)
Balance at September 30, 2014	$	—		$	—		$	—

Revolving Credit Facility	12 Months Ended
Revolving Credit Facility	Sep. 30, 2015
Text Block [Abstract]
Revolving Credit Facility	8. Revolving Credit Facility On November 4, 2013, the Company entered into a three-year $20.0 million secured revolving credit facility. The Company’s obligations under the credit facility are secured by substantially all of its and its subsidiaries’ assets, other than intellectual property and real estate. Borrowings under the credit facility, if any, will bear interest at a benchmark rate plus a margin ranging from 1.375% to 2.00% based on the Company’s leverage ratio. A facility fee is payable on unused commitments at a rate of 0.20% per annum. On November 20, 2015, the credit facility was further amended and modified to increase the size of stock repurchases that may be effected by the Company to $30.0 million without the consent of the lender. In connection with the credit facility, the Company is required to maintain certain financial covenants related to a maximum leverage ratio and a minimum earnings before income tax, depreciation and amortization (“EBITDA”) amount and to comply with nonfinancial covenants. As of September 30, 2015, the Company has no debt outstanding and was in compliance with all financial.

Income Taxes

12 Months Ended

Sep. 30, 2015

Income Tax Disclosure [Abstract]

Income Taxes

9. Income Taxes

The Company accounts for income taxes under the asset and liability method prescribed in accounting guidance. Deferred tax assets and liabilities are recognized for the future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases. A valuation allowance is provided when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The ultimate realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. Management considers the scheduled reversal of deferred tax liabilities, projected future taxable income and tax planning strategies in this assessment. Deferred tax assets and liabilities are measured using the enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in income in the period that includes the enactment date of such change.

Income taxes from continuing operations in the accompanying consolidated statements of income for the fiscal years ended September 30 are as follows (in thousands):

	2015		2014			2013
Current provision:
Federal	$	6,065	$	6,470		$	6,048
State and foreign		136		147			225
Total current provision		6,201		6,617			6,273
Deferred provision (benefit):
Federal		58		(347	)		(552	)
State		35		(5	)		60
Total deferred provision (benefit)		93		(352	)		(492	)
Total provision	$	6,294	$	6,265		$	5,781

The reconciliation of the difference between amounts calculated at the statutory U.S. federal tax rate of 35% for the fiscal years ended September 30 and the Company’s effective tax rate from continuing operations is as follows (in thousands):

	2015			2014			2013
Amount at statutory U.S. federal income tax rate	$	6,385		$	6,465		$	7,126
Change because of the following items:
State income taxes, net of federal benefit		67			118			278
Stock-based compensation		16			21			25
Valuation allowance change		348			120			(699	)
Tax reserve change		34			(121	)		(128	)
Federal manufacturing deduction		(268	)		(235	)		(266	)
Federal research and development credit		(74	)		(67	)		(324	)
Other		(214	)		(36	)		(231	)
Income tax provision	$	6,294		$	6,265		$	5,781

The federal research and development tax credit for fiscal 2015 and 2014 includes the benefit generated for the period from October 1, 2014 to December 31, 2014 and October 1, 2013 to December 31, 2013, respectively, prior to the expiration of the benefit in each period. The federal research and development credit for fiscal 2013 above includes $0.2 million related to a retroactive 2012 U.S. research and development tax credit for the period from January 1, 2012 to December 31, 2012 which was recognized in fiscal 2013 as a discrete tax benefit resulting from the January 2013 signing of the American Taxpayer Relief Act of 2012.

The Company recorded an income tax benefit from discontinued operations of $0.1 million in fiscal 2014, an income tax expense of $0.5 million in fiscal 2013, an income tax expense of $1.1 million in fiscal 2012 and an income tax benefit of $0.6 million associated with the sale of discontinued operations assets in fiscal 2012.

The components of deferred income taxes consisted of the following as of September 30 and result from differences in the recognition of transactions for income tax and financial reporting purposes (in thousands):

	2015			2014
Depreciable assets	$	1,618		$	1,612
Deferred revenue		96			101
Accruals and reserves		145			324
Stock-based compensation		4,194			4,373
Impaired strategic investments		4,186			3,674
Unrealized gains on investments		—			(550	)
Capital loss carryforward		1,456			1,650
Other		1,276			764
Valuation allowance		(5,721	)		(4,836	)
Total deferred tax assets		7,250			7,112
Less current deferred tax assets		(546	)		(394	)
Noncurrent deferred tax assets	$	6,704		$	6,718

As of September 30, 2015 and 2014, the Company recorded a deferred tax asset valuation allowance of $5.7 million and $4.8 million, respectively. The valuation allowances are primarily related to capital loss carryforwards created by impairment losses on strategic investments and state R&D credit carryforwards. The increase in fiscal 2015 primarily relates to creation of valuation allowances associated with a loss created by the impairment of certain of the Company’s strategic investments and an increase in state research and development tax credit carry-forwards.

Unrecognized tax benefits are the differences between a tax position taken, or expected to be taken in a tax return, and the benefit recognized for accounting purposes pursuant to accounting guidance. A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, is as follows (in thousands):

	2015			2014			2013
Beginning of fiscal year	$	1,216		$	1,300		$	1,435
Increases in tax positions for prior years		50			43			27
Decreases in tax positions for prior years		(10	)		(1	)		(278	)
Increases in tax positions for current year		146			149			122
Lapse of the statute of limitations		(154	)		(275	)		(6	)
End of fiscal year	$	1,248		$	1,216		$	1,300

The total amount of unrecognized tax benefits excluding interest and penalties that, if recognized, would affect the effective tax rate as of September 30, 2015, 2014 and 2013, respectively, are $0.9 million, $0.9 million and $1.0 million. Currently, the Company does not expect the liability for unrecognized tax benefits to change significantly in the next 12 months with the above balances classified on the consolidated balance sheets in other long-term liabilities. Interest and penalties related to unrecognized tax benefits are recorded in income tax expense. As of September 30, 2015, 2014 and 2013, a gross balance of $0.6 million, $0.6 million and $0.7 million, respectively, has been accrued related to the unrecognized tax benefits balance for interest and penalties.

The Company files income tax returns, including returns for its subsidiaries, in the U.S. federal jurisdiction and in various state jurisdictions. Uncertain tax positions are related to tax years that remain subject to examination. The Internal Revenue Service (“IRS”) commenced an examination of the Company’s U.S. income tax return for fiscal 2012 in the first quarter of fiscal 2014. The examination was completed in the fourth quarter of fiscal 2014 with a payment made associated with a timing adjustment. U.S. income tax returns for years prior to fiscal 2012 are no longer subject to examination by federal tax authorities. For tax returns for state and local jurisdictions, the Company is no longer subject to examination for tax years generally before fiscal 2005.

Defined Contribution Plan	12 Months Ended
Defined Contribution Plan	Sep. 30, 2015
Compensation And Retirement Disclosure [Abstract]
Defined Contribution Plan	10. Defined Contribution Plan The Company has a 401(k) retirement and savings plan for the benefit of qualifying employees. The Company matches 50% of employee contributions on the first 6% of eligible compensation. Company contributions totaling $0.3 million, $0.2 million and $0.2 million have been expensed in the years ended September 30, 2015, 2014 and 2013, respectively.

Amounts Reclassified Out of Accumulated Other Comprehensive Income	12 Months Ended
	Sep. 30, 2015
Equity [Abstract]
Amounts Reclassified Out of Accumulated Other Comprehensive Income	11. Amounts Reclassified Out of Accumulated Other Comprehensive Income Amounts reclassified out of Accumulated Other Comprehensive Income (“AOCI”) totaled $0.3 million and $0.1 million on a pre-tax basis for the fiscal years ended September 30, 2015 and 2014, respectively. The amounts reclassified out of AOCI are associated with unrealized gains on available-for-sale securities that were realized on the sale of the securities and are presented in other income, net in the consolidated statements of income.

- Definition

The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 15
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e689-108580

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-URI http://asc.fasb.org/extlink&oid=36458714&loc=SL7669619-108580

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e640-108580

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 17
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e716-108580

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e709-108580

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e637-108580

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 14
-URI http://asc.fasb.org/extlink&oid=36458714&loc=d3e681-108580

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Glossary Reclassification Adjustments
-URI http://asc.fasb.org/extlink&oid=6522872

+ Details

Commitments and Contingencies

12 Months Ended

Sep. 30, 2015

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies

12. Commitments and Contingencies

Litigation. From time to time, the Company has been, and may become, involved in various legal actions involving its operations, products and technologies, including intellectual property and employment disputes. The outcomes of these legal actions are not within the Company’s complete control and may not be known for prolonged periods of time. In some actions, the claimants seek damages, as well as other relief, including injunctions barring the sale of products that are the subject of the lawsuit, which, if granted, could require significant expenditures or result in lost revenue. The Company records a liability in the consolidated financial statements for these actions when a loss is known or considered probable and the amount can be reasonably estimated. If the reasonable estimate of a known or probable loss is a range, and no amount within the range is a better estimate, the minimum amount of the range is accrued. If a loss is possible but not known or probable, and can be reasonably estimated, the estimated loss or range of loss is disclosed. In most cases, significant judgment is required to estimate the amount and timing of a loss to be recorded.

In the Company’s Quarterly Reports on Form 10-Q for the periods ended March 31, 2015, and June 30, 2015, it was disclosed a notice was received from a customer alleging an overpayment of approximately $5.7 million in royalties covering the period January 2009 through September 2014 (the “Claim”). On September 29, 2015, the Company entered into a settlement and release agreement resolving the Claim. Under the agreement, among other things, (a) the Company agreed to pay the customer $2.5 million to settle the Claim, (b) the customer agreed to pay the Company approximately $0.5 million for undisputed royalties that were unpaid and were not previously recognized, during fiscal 2015, and (c) the Company and the customer agreed to a mutual release relating to the Claim and certain other claims by the Company for royalties owed by the customer. In connection with the settlement, in the fourth quarter of fiscal 2015, the Company recognized revenue of approximately $0.5 million and recorded a charge of approximately $2.5 million.

InnoCore Technologies BV. In March 2006, the Company entered into a license agreement whereby SurModics obtained an exclusive license to a drug delivery coating for licensed products within the vascular field which included peripheral, coronary and neurovascular biodurable stent product. The license requires an annual minimum payment of 200,000 euros (equivalent to $223,000 using a euro to US $ exchange rate of 1.11707 as of September 30, 2015) until the last patent expires which is currently estimated to be September 2027. The total minimum future payments associated with this license are approximately $2.7 million. The license is currently utilized with one of SurModics’ drug delivery customers.

PR Pharmaceuticals, Inc. In November 2008, SurModics Pharmaceuticals acquired certain contracts and assets of PR Pharma to enhance its portfolio of drug delivery technologies for the pharmaceutical and biotechnology industries. The Company agreed to indemnify Evonik, for a period of five years, for up to $2.5 million of contingent consideration obligations owed to the sellers of PR Pharma related to a future patent issuance milestone when it sold substantially all of the SurModics Pharmaceuticals assets to Evonik on November 17, 2011. In the fourth quarter of fiscal 2014, SurModics submitted a bid of less than $0.1 million related to our indemnification obligations to Evonik related to a contingent consideration matter associated with the PR Pharma intellectual property purchased by Evonik in the Pharma Sale. SurModics was notified in October 2014 that the bid was accepted with a payment made at that time.

Operating Leases. The Company leases certain facilities under noncancelable operating lease agreements. Rent expense for the years ended September 30, 2015, 2014 and 2013 was $0.1 million for each period. Annual commitments pursuant to operating lease agreements are as follows (in thousands):

Year Ended September 30,
2016	$	73
2017		68
2018		70
2019		72
2020		74
Thereafter		12
Total minimum lease payments	$	369

Operating Segment Information

12 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Operating Segment Information

13. Operating Segment Information

The accounting standards for reporting information about operating segments define operating segments as components of an enterprise about which separate financial information is available that is evaluated regularly by the chief operating decision maker, who is the Company’s Chief Executive Officer, in deciding how to allocate resources and in assessing performance. For financial accounting and reporting purposes, the Company reports its results for the two reportable segments as follows: (1) the Medical Device unit, which is comprised of surface modification coating technologies to improve access, deliverability, and predictable deployment of medical devices, as well as drug delivery coating technologies to provide site-specific drug delivery from the surface of a medical device, with end markets that include coronary, peripheral, and neuro-vascular, and urology, among others, and (2) the In Vitro Diagnostics unit, which consists of component products and technologies for diagnostic test kits and biomedical research applications, with products that include protein stabilization reagents, substrates, antigens and surface coatings.

The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, for the years ended September 30, as follows (in thousands):

	2015			2014			2013
Revenue:
Medical Device	$	45,944		$	43,068		$	41,153
In Vitro Diagnostics		15,954			14,371			14,979
Total revenue	$	61,898		$	57,439		$	56,132

Operating income (loss):
Medical Device	$	21,192		$	22,636		$	21,164
In Vitro Diagnostics		4,484			3,459			4,222
Total segment operating income		25,676			26,095			25,386
Corporate		(6,587	)		(7,519	)		(6,566	)
Total operating income from continuing operations	$	19,089		$	18,576		$	18,820

Depreciation and amortization:
Medical Device	$	1,138		$	1,136		$	1,255
In Vitro Diagnostics		873			850			864
Corporate		794			729			767
Total depreciation and amortization	$	2,805		$	2,715		$	2,886

The Corporate category includes expenses for administrative corporate functions, such as executive, corporate accounting, legal, human resources and Board of Directors related, that have not been fully allocated to the Medical Device and In Vitro Diagnostics segments. Corporate also includes expenses, such as litigation, which are not specific to a segment and thus not allocated to the operating segments.

Corporate segment results above for fiscal 2014 include increased stock option expense of $0.9 million related to a modification of equity awards granted to Board members.

Corporate segment results above for fiscal 2013 include restructuring charges of $0.5 million and recovery of legal fees associated with the SRI litigation of $1.0 million.

Asset information by segment is not presented because the Company does not provide its chief operating decision maker assets by segment, as the data is not readily available.

Major Customers

Revenue from customers that equaled or exceeded 10% of total revenue was as follows for the years ended September 30:

		2015				2014				2013
Medtronic			26	%			19	%			19	%

The revenue from the customer listed is derived from two primary sources: licensing and product sales. The percentage of revenue increased in fiscal 2015 as a result of Medtronic’s merger with Covidien PLC on January 26, 2015.

Geographic Revenue

Geographic revenue was as follows for the years ended September 30:

	2015			2014			2013
Domestic		77	%		78	%		79	%
Foreign		23	%		22	%		21	%

- Definition

The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 34
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8981-108599

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 41
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9038-108599

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 33
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8971-108599

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8595-108599

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8380-108599

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 32
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8933-108599

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 26
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8844-108599

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 35
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8984-108599

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 40
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9031-108599

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 42
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e9054-108599

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8538-108599

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 29
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8864-108599

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 31
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8924-108599

Reference 14: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 30
-URI http://asc.fasb.org/extlink&oid=51669610&loc=d3e8906-108599

+ Details

Subsequent Events	12 Months Ended
Subsequent Events	Sep. 30, 2015
Subsequent Events [Abstract]
Subsequent Events	14. Subsequent Events On November 6, 2015, the Company’s Board of Director authorized it to repurchase up to an additional $20.0 million of the Company’s outstanding stock in open-market purchases, privately negotiated transactions, block trades, accelerated share repurchase transactions, tender offers or by any combination of such methods. With this authorization, the Company may currently repurchase up to $30.0 million of its outstanding stock. The authorization has no fixed expiration date. On November 20, 2015, the Company acquired 100% of the outstanding common shares and voting shares of Creagh located in Ballinasloe, Ireland. The results of Creagh’s operations will be included in the Company’s consolidated financial statements as of the Creagh acquisition date. The acquisition was financed with cash on hand. The Company acquired Creagh for up to €30 million ($32.1 million), including an upfront payment of €18 million ($19.3 million), and up to €12 million ($12.8 million) based on achievement of revenue and value-creating operational milestones through September 30, 2018. The payment of the milestones will occur in the quarter ending December 31, 2018. Creagh is a provider of innovative, efficient and cost-effective design and manufacture of high-quality PTA balloon catheters. Since 2006, Creagh has grown its technical and product capability with PTA products approved throughout the world, including Europe, the United States, and Japan. With these resources, the Company is uniquely positioned to offer a total solutions approach from product design and development, through in-house extrusion, balloon forming, top-assembly, packaging and regulatory capabilities to approved products for exclusive distribution. The acquisition is a major step forward in the Company’s strategy to transform its Medical Device segment from being a provider of coatings technologies, to offering whole-product solutions to medical device customers in the large and growing global interventional vascular market. The Company has excluded the purchase price allocations and pro forma disclosures for the Creagh acquisition as the initial accounting is currently incomplete. The Company is currently in the process of obtaining an initial valuation related to the acquired assets and liabilities. On November 20, 2015, the Company’s credit facility was amended and modified to increase the size of stock repurchases that can be effected by the Company by $20.0 million.

Quarterly Financial Data (Unaudited)

12 Months Ended

Sep. 30, 2015

Quarterly Financial Information Disclosure [Abstract]

Quarterly Financial Data (Unaudited)

15. Quarterly Financial Data (Unaudited)

The following is a summary of the unaudited quarterly results for the years ended September 30, 2015 and 2014 (in thousands, except per share data).

	First Quarter		Second Quarter		Third Quarter			Fourth Quarter
Fiscal 2015
Total revenue	$	14,205	$	14,415	$	15,914		$	17,364
Operating income from continuing operations		5,034		3,932		5,857			4,266
Income from continuing operations		3,614		3,051		3,924			1,358
Loss from discontinued operations		—		—		—			—
Net income		3,614		3,051		3,924			1,358
Basic income (loss) per share(1):
Continuing operations		0.27		0.24		0.30			0.10
Discontinued operations		0.00		0.00		(0.00	)		(0.00	)
Net income		0.27		0.24		0.30			0.10
Diluted income (loss) per share(1):
Continuing operations		0.27		0.23		0.30			0.10
Discontinued operations		0.00		0.00		(0.00	)		(0.00	)
Net income		0.27		0.23		0.30			0.10

Fiscal 2014
Total revenue	$	13,883	$	13,604	$	14,616		$	15,336
Operating income from continuing operations		4,329		3,480		5,333			5,434
Income from continuing operations		3,630		2,459		3,674			2,444
Loss from discontinued operations		—		—		(76	)		(100	)
Net income		3,630		2,459		3,598			2,344
Basic income (loss) per share(1):
Continuing operations		0.26		0.18		0.27			0.18
Discontinued operations		0.00		0.00		(0.01	)		(0.01	)
Net income		0.26		0.18		0.26			0.17
Diluted income (loss) per share(1):
Continuing operations		0.26		0.18		0.27			0.18
Discontinued operations		0.00		0.00		(0.01	)		(0.01	)
Net income		0.26		0.18		0.26			0.17

(1)	The sum of the quarterly income (loss) per share amounts may not equal the annual income (loss) per share total because of changes in the weighted average number of shares outstanding that occurred during the year.

In the fourth quarter of fiscal 2015, the Company recorded expense related to the settlement of a claim of $2.5 million, a $1.5 million impairment loss on a strategic investment and recognized $0.8 million in previously contingent royalties.

In the third quarter of fiscal 2015, the Company recorded a $0.6 million one-time customer royalty payment related to periods prior to the third quarter fiscal 2015.

In the second quarter of fiscal 2015, the Company recorded a $0.5 million gain on a strategic investment in Intersect ENT shares.

In the fourth quarter of fiscal 2014, the Company recorded a $1.2 million impairment loss on strategic investments.

In the second quarter of fiscal 2014, the Company recorded a $0.9 million stock-based compensation expense related to modification of Board of Directors options and other equity awards vesting periods.

In the first quarter of fiscal 2014, the Company recorded a gain of $0.7 million associated with contingent consideration paid associated with the sale of a strategic investment.

Summary of Significant Accounting Policies and Select Balance Sheet Information (Policies)

12 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Cash and Cash Equivalents

Investments

	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
U.S. government and government agency obligations	$	7,397	$	12	$	(15	)	$	7,394
Mortgage-backed securities		5,576		43		(74	)		5,545
Municipal bonds		1,173		5		(3	)		1,175
Asset-backed securities		2,370		3		(4	)		2,369
Corporate bonds		1,829		6		(5	)		1,830
Equity securities		2		1,548		—			1,550
Total	$	18,347	$	1,617	$	(101	)	$	19,863

The following table summarizes sales of available-for-sale securities for the years ended September 30, 2015, 2014 and 2013 (in thousands):

	2015			2014			2013
Proceeds from sales	$	22,199		$	162,673		$	44,853
Gross realized gains	$	548		$	134		$	179
Gross realized losses	$	(73	)	$	(1	)	$	(43	)

There were no held-to-maturity debt securities at September 30, 2015 or 2014.

Inventories

	2015		2014
Raw materials	$	1,264	$	1,056
Finished products		1,715		1,761
Total	$	2,979	$	2,817

Property and Equipment

Property and equipment consisted of the following components as of September 30 (in thousands):

	Useful Life	2015			2014
	(In years)
Land	N/A	$	4,359		$	4,359
Laboratory fixtures and equipment	3 to 10		12,941			12,858
Buildings and improvements	3 to 20		16,444			16,114
Office furniture and equipment	3 to 10		3,473			3,060
Construction-in-progress			1,168			1,158
Less accumulated depreciation			(25,417	)		(24,416	)
Property and equipment, net		$	12,968		$	13,133

Other Assets

Other assets consisted principally of strategic investments as of September 30 as follows (in thousands):

	2015		2014
CeloNova BioSciences, Inc.	$	—	$	1,500
ViaCyte, Inc.		479		479
Other assets, net	$	479	$	1,979

Intangible Assets

Intangible assets consisted of the following as of September 30 (in thousands):

	2015
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists		9.0	$	5,132	$	(4,363	)	$	769
Core technology		8.0		530		(530	)		0
Non-compete		5.0		230		(12	)		218
Patents and other	16.8			2,321		(1,128	)		1,193
Subtotal				8,213		(6,033	)		2,180
Unamortized intangible assets:
Trademarks				580		—			580
Total			$	8,793	$	(6,033	)	$	2,760

	2014
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists		9.0	$	4,857	$	(3,813	)	$	1,044
Core technology		8.0		530		(475	)		55
Patents and other		16.8		2,256		(989	)		1,267
Subtotal				7,643		(5,277	)		2,366
Unamortized intangible assets:
Trademarks				580		—			580
Total			$	8,223	$	(5,277	)	$	2,946

Based on the intangible assets in service as of September 30, 2015, estimated amortization expense for each of the next five fiscal years is as follows (in thousands):

2016	$	690
2017		279
2018		233
2019		233
2020	221

Goodwill

Valuation of Long-Lived Assets

Revenue Recognition

Taxes collected from customers and remitted to governmental authorities are excluded from revenue and amounted to $0.1 million for each of the years ended September 30, 2015, 2014 and 2013.

Royalties and license fees

Revenue related to a performance milestone is recognized upon the achievement of the milestone, as defined in the respective agreements and provided the following conditions have been met:

•

The milestone payment is non-refundable;

•

The milestone involved a significant degree of risk, and was not reasonably assured at the inception of the arrangement;

•

Accomplishment of the milestone involved substantial effort;

•

The amount of the milestone payment is commensurate with the related effort and risk; and

•

A reasonable amount of time passed between the initial license payment and the first and subsequent milestone payments.

If these conditions have not been met, the milestone payment is deferred and recognized over the term of the agreement.

Product sales

Research and development

Arrangements with multiple deliverables

Arrangements with multiple deliverables. Revenue arrangements with multiple deliverables requires the Company to:

(i) disclose whether multiple deliverables exist, how the deliverables in an arrangement should be separated, and how the consideration should be allocated;

(iii) allocate revenue using the relative selling price method.

Deferred Revenue

Customer advances are accounted for as a liability until all criteria for revenue recognition have been met.

Customer Concentrations

Research and Development

Use of Estimates

Income Per Share Data

The following table sets forth the denominator for the computation of basic and diluted income per share (in thousands):

	2015		2014		2013
Net income from continuing operations available to common shareholders	$	11,947	$	12,207	$	14,579

Basic weighted average shares outstanding		13,029		13,632		14,464
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units and performance shares		260		244		267
Diluted weighted average shares outstanding		13,289		13,876		14,731

New Accounting Pronouncements

Accounting Standards to be Adopted

No other new accounting pronouncement issued or effective has had, or is expected to have, a material impact on the Company’s consolidated financial statements..

Summary of Significant Accounting Policies and Select Balance Sheet Information (Tables)

12 Months Ended

Sep. 30, 2015

Accounting Policies [Abstract]

Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available-for-Sale Securities

The amortized cost, unrealized holding gains and losses, and fair value of available-for-sale securities as of September 30, 2014 were as follows (in thousands):

	Amortized Cost		Unrealized Gains		Unrealized Losses			Fair Value
U.S. government and government agency obligations	$	7,397	$	12	$	(15	)	$	7,394
Mortgage-backed securities		5,576		43		(74	)		5,545
Municipal bonds		1,173		5		(3	)		1,175
Asset-backed securities		2,370		3		(4	)		2,369
Corporate bonds		1,829		6		(5	)		1,830
Equity securities		2		1,548		—			1,550
Total	$	18,347	$	1,617	$	(101	)	$	19,863

Sales of Available-for-Sale Securities

The following table summarizes sales of available-for-sale securities for the years ended September 30, 2015, 2014 and 2013 (in thousands):

	2015			2014			2013
Proceeds from sales	$	22,199		$	162,673		$	44,853
Gross realized gains	$	548		$	134		$	179
Gross realized losses	$	(73	)	$	(1	)	$	(43	)

Components of Inventories

Inventories consisted of the following components as of September 30 (in thousands):

	2015		2014
Raw materials	$	1,264	$	1,056
Finished products		1,715		1,761
Total	$	2,979	$	2,817

Schedule of Property, Plant and Equipment

Property and equipment consisted of the following components as of September 30 (in thousands):

	Useful Life	2015			2014
	(In years)
Land	N/A	$	4,359		$	4,359
Laboratory fixtures and equipment	3 to 10		12,941			12,858
Buildings and improvements	3 to 20		16,444			16,114
Office furniture and equipment	3 to 10		3,473			3,060
Construction-in-progress			1,168			1,158
Less accumulated depreciation			(25,417	)		(24,416	)
Property and equipment, net		$	12,968		$	13,133

Schedule of Other Assets Consist Principally of Strategic Investments

Other assets consisted principally of strategic investments as of September 30 as follows (in thousands):

	2015		2014
CeloNova BioSciences, Inc.	$	—	$	1,500
ViaCyte, Inc.		479		479
Other assets, net	$	479	$	1,979

Schedule of Intangible Assets

Intangible assets consisted of the following as of September 30 (in thousands):

	2015
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists		9.0	$	5,132	$	(4,363	)	$	769
Core technology		8.0		530		(530	)		0
Non-compete		5.0		230		(12	)		218
Patents and other	16.8			2,321		(1,128	)		1,193
Subtotal				8,213		(6,033	)		2,180
Unamortized intangible assets:
Trademarks				580		—			580
Total			$	8,793	$	(6,033	)	$	2,760

	2014
	Weighted Average Original Life (Years)		Gross Carrying Amount		Accumulated Amortization			Net
Definite-lived intangible assets:
Customer lists		9.0	$	4,857	$	(3,813	)	$	1,044
Core technology		8.0		530		(475	)		55
Patents and other		16.8		2,256		(989	)		1,267
Subtotal				7,643		(5,277	)		2,366
Unamortized intangible assets:
Trademarks				580		—			580
Total			$	8,223	$	(5,277	)	$	2,946

Estimated Amortization Expense

Based on the intangible assets in service as of September 30, 2015, estimated amortization expense for each of the next five fiscal years is as follows (in thousands):

2016	$	690
2017		279
2018		233
2019		233
2020	221

Denominator for Computation of Basic and Diluted Income Per Share

The following table sets forth the denominator for the computation of basic and diluted income per share (in thousands):

	2015		2014		2013
Net income from continuing operations available to common shareholders	$	11,947	$	12,207	$	14,579

Basic weighted average shares outstanding		13,029		13,632		14,464
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units and performance shares		260		244		267
Diluted weighted average shares outstanding		13,289		13,876		14,731

- Definition

Tabular disclosure of available-for-sale securities which includes, but is not limited to, changes in the cost basis and fair value, fair value and gross unrealized gain (loss), fair values by type of security, contractual maturity and classification, amortized cost basis, contracts to acquire securities to be accounted for as available-for-sale, debt maturities, transfers to trading, change in net unrealized holding gain (loss) net of tax, continuous unrealized loss position fair value, aggregate losses qualitative disclosures, other than temporary impairment (OTTI) losses or other disclosures related to available for sale securities.

+ References + Details

Discontinued Operations (Tables)

12 Months Ended

Sep. 30, 2015

Discontinued Operations And Disposal Groups [Abstract]

Operating Results from Discontinued Operations

The following is a summary of the operating results of SurModics Pharmaceuticals discontinued operations for the years ended September 30 (in thousands):

	2014			2013
Total revenue	$	—		$	—

(Loss) income from discontinued operations	$	(260	)	$	1,136
Income tax benefit (provision)		84			(548	)
(Loss) income from discontinued operations, net of income taxes	$	(176	)	$	588
Loss on sale of discontinued operations	$	—		$	—
Income tax benefit		—			—
Loss on sale of discontinued operations, net of income Taxes	$	—		$	—

- Definition

Tabular disclosure of information related to a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=51716988&loc=SL51721533-107759

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721665-107760

Reference 3: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1474-107760

Reference 4: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=51717284&loc=d3e1361-107760

Reference 5: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721683-107760

Reference 6: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51719941&loc=SL51724579-110230

Reference 7: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5C
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721675-107760

Reference 8: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 4A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721663-107760

Reference 9: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=51719941&loc=d3e2941-110230

Reference 10: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5B
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721673-107760

Reference 11: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 3A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721659-107760

Reference 12: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5A
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721671-107760

Reference 13: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 20
-Section 50
-Paragraph 5D
-URI http://asc.fasb.org/extlink&oid=51717284&loc=SL51721677-107760

+ Details

Fair Value Measurements (Tables)

12 Months Ended

Sep. 30, 2015

Fair Value Disclosures [Abstract]

Assets and Liabilities Measured at Fair Value on Recurring Basis

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2015 (in thousands):

	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value as of September 30, 2015
Assets:
Cash equivalents	$	—	$	53,591	$	—	$	53,591
Total assets measured at fair value	$	—	$	53,591	$	—	$	53,591

The following table presents information about the Company’s assets and liabilities measured at fair value on a recurring basis as of September 30, 2014 (in thousands):

	Quoted Prices in Active Markets for Identical Instruments (Level 1)		Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Total Fair Value as of September 30, 2014
Assets:
Cash equivalents	$	—	$	40,100	$	—	$	40,100
Available-for-sale equity securities		1,550		—		—		1,550
Available-for-sale debt securities:
U.S. government and government agency obligations		—		7,394		—		7,394
Mortgage-backed securities		—		5,545		—		5,545
Municipal bonds		—		1,175		—		1,175
Asset-backed securities		—		2,369		—		2,369
Corporate bonds		—		1,830		—		1,830
Total assets measured at fair value	$	1,550	$	58,413	$	—	$	59,963

Stock-Based Compensation Plans (Tables)

12 Months Ended

Sep. 30, 2015

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation Expenses

The Company’s stock-based compensation expenses for the years ended September 30 were allocated to the following expense categories

	2015		2014		2013
Product costs	$	24	$	16	$	22
Research and development		226		175		180
Selling, general and administrative		2,131		3,146		2,350
Total stock-based compensation expense	$	2,381	$	3,337	$	2,552

Assumptions Used in Stock Option Plans

The assumptions used as inputs in the model for the years ended September 30 were as follows:

	2015			2014			2013
Risk-free interest rates		1.43	%		1.19	%		0.60	%
Expected life	4.5 years			4.6 years			4.8 years
Expected volatility		43	%		45	%		49	%
Dividend yield		0	%		0	%		0	%

Schedule of Stock Option Activity

The following table summarizes all stock options activity and stock options outstanding and exercisable under the stock option plans during fiscal 2015, 2014 and 2013:

	Number of Shares			Weighted Average Exercise Price
Outstanding at September 30, 2012		1,325,438		$	21.25
Granted		178,924			20.85
Exercised		(10,273	)		14.40
Forfeited		(125,105	)		33.47
Outstanding at September 30, 2013		1,368,984			20.13
Granted		138,837			22.71
Exercised		(190,434	)		14.42
Forfeited		(106,768	)		31.26
Outstanding at September 30, 2014		1,210,619			20.35
Granted		164,401			21.24
Exercised		(166,422	)		14.54
Forfeited		(90,590	)		35.35
Outstanding at September 30, 2015		1,118,008			20.10
Exercisable at September 30, 2015		797,045		$	20.04

Schedule of Restricted Stock Awards Activity

The following table summarizes all restricted stock awards activity during fiscal 2015, 2014 and 2013:

	Number of Shares			Weighted Average Grant Price
Balance at September 30, 2012		4,000		$	22.11
Vested		5,234			23.88
Forfeited		(4,000	)		22.11
Balance at September 30, 2013		5,234			23.88
Granted		22,155			22.67
Vested		(7,991	)		23.98
Forfeited		(774	)		22.58
Balance at September 30, 2014		18,624			22.45
Granted		18,073			21.84
Vested		(7,606	)		22.28
Forfeited		(1,316	)		22.16
Balance at September 30, 2015		27,775		$	22.12

Schedule of Fair Value at the Date of Grant

The aggregate number of shares that could be awarded to key employees if the minimum, target and maximum performance goals are met, based upon the fair value at the date of grant is as follows:

Performance Period	Minimum Shares		Target Shares		Maximum Shares
Fiscal 2013 – 2015		8,551		42,753		85,506
Fiscal 2014 - 2016		7,861		39,303		78,606
Fiscal 2015 – 2017		8,440		42,199		84,398

Restructuring Charges (Tables)

12 Months Ended

Sep. 30, 2015

Restructuring And Related Activities [Abstract]

Restructuring Accrual Activities

The following table summarizes the restructuring accrual activity (in thousands):

	Employee Severance and Benefits			Facility- Related Costs			Total
Balance at September 30, 2012	$	10		$	182		$	192
Accrual/(reversal) during the year		534			(58	)		476
Cash payments		(145	)		(107	)		(252	)
Balance at September 30, 2013	$	399		$	17		$	416
Accrual/(reversal) during the year		(20	)		(2	)		(22	)
Cash payments		(379	)		(15	)		(394	)
Balance at September 30, 2014	$	—		$	—		$	—

Income Taxes (Tables)

12 Months Ended

Sep. 30, 2015

Income Tax Disclosure [Abstract]

Schedule of Income Taxes from Continuing Operations

Income taxes from continuing operations in the accompanying consolidated statements of income for the fiscal years ended September 30 are as follows (in thousands):

	2015		2014			2013
Current provision:
Federal	$	6,065	$	6,470		$	6,048
State and foreign		136		147			225
Total current provision		6,201		6,617			6,273
Deferred provision (benefit):
Federal		58		(347	)		(552	)
State		35		(5	)		60
Total deferred provision (benefit)		93		(352	)		(492	)
Total provision	$	6,294	$	6,265		$	5,781

Schedule of Reconciliation Difference of Income Taxes

	2015			2014			2013
Amount at statutory U.S. federal income tax rate	$	6,385		$	6,465		$	7,126
Change because of the following items:
State income taxes, net of federal benefit		67			118			278
Stock-based compensation		16			21			25
Valuation allowance change		348			120			(699	)
Tax reserve change		34			(121	)		(128	)
Federal manufacturing deduction		(268	)		(235	)		(266	)
Federal research and development credit		(74	)		(67	)		(324	)
Other		(214	)		(36	)		(231	)
Income tax provision	$	6,294		$	6,265		$	5,781

Schedule of Deferred Income Taxes

	2015			2014
Depreciable assets	$	1,618		$	1,612
Deferred revenue		96			101
Accruals and reserves		145			324
Stock-based compensation		4,194			4,373
Impaired strategic investments		4,186			3,674
Unrealized gains on investments		—			(550	)
Capital loss carryforward		1,456			1,650
Other		1,276			764
Valuation allowance		(5,721	)		(4,836	)
Total deferred tax assets		7,250			7,112
Less current deferred tax assets		(546	)		(394	)
Noncurrent deferred tax assets	$	6,704		$	6,718

Summary of Reconciliation of Unrecognized Tax Benefits

A reconciliation of the beginning and ending amount of unrecognized tax benefits, excluding interest and penalties, is as follows (in thousands):

	2015			2014			2013
Beginning of fiscal year	$	1,216		$	1,300		$	1,435
Increases in tax positions for prior years		50			43			27
Decreases in tax positions for prior years		(10	)		(1	)		(278	)
Increases in tax positions for current year		146			149			122
Lapse of the statute of limitations		(154	)		(275	)		(6	)
End of fiscal year	$	1,248		$	1,216		$	1,300

Commitments and Contingencies (Tables)

12 Months Ended

Sep. 30, 2015

Commitments And Contingencies Disclosure [Abstract]

Summary of Annual Commitments Pursuant to Operating Lease Agreements

Annual commitments pursuant to operating lease agreements are as follows (in thousands):

Year Ended September 30,
2016	$	73
2017		68
2018		70
2019		72
2020		74
Thereafter		12
Total minimum lease payments	$	369

Operating Segment Information (Tables)

12 Months Ended

Sep. 30, 2015

Segment Reporting [Abstract]

Segment Revenue, Operating Income and Depreciation and Amortization

The tables below present segment revenue, operating income from continuing operations and depreciation and amortization, for the years ended September 30, as follows (in thousands):

	2015			2014			2013
Revenue:
Medical Device	$	45,944		$	43,068		$	41,153
In Vitro Diagnostics		15,954			14,371			14,979
Total revenue	$	61,898		$	57,439		$	56,132

Operating income (loss):
Medical Device	$	21,192		$	22,636		$	21,164
In Vitro Diagnostics		4,484			3,459			4,222
Total segment operating income		25,676			26,095			25,386
Corporate		(6,587	)		(7,519	)		(6,566	)
Total operating income from continuing operations	$	19,089		$	18,576		$	18,820

Depreciation and amortization:
Medical Device	$	1,138		$	1,136		$	1,255
In Vitro Diagnostics		873			850			864
Corporate		794			729			767
Total depreciation and amortization	$	2,805		$	2,715		$	2,886

Revenue from Major Customers

Revenue from customers that equaled or exceeded 10% of total revenue was as follows for the years ended September 30:

		2015				2014				2013
Medtronic			26	%			19	%			19	%

Geographic Revenue

Geographic revenue was as follows for the years ended September 30:

	2015			2014			2013
Domestic		77	%		78	%		79	%
Foreign		23	%		22	%		21	%

Quarterly Financial Data (Unaudited) (Tables)

12 Months Ended

Sep. 30, 2015

Quarterly Financial Information Disclosure [Abstract]

Summary of Unaudited Quarterly Results

The following is a summary of the unaudited quarterly results for the years ended September 30, 2015 and 2014 (in thousands, except per share data).

	First Quarter		Second Quarter		Third Quarter			Fourth Quarter
Fiscal 2015
Total revenue	$	14,205	$	14,415	$	15,914		$	17,364
Operating income from continuing operations		5,034		3,932		5,857			4,266
Income from continuing operations		3,614		3,051		3,924			1,358
Loss from discontinued operations		—		—		—			—
Net income		3,614		3,051		3,924			1,358
Basic income (loss) per share(1):
Continuing operations		0.27		0.24		0.30			0.10
Discontinued operations		0.00		0.00		(0.00	)		(0.00	)
Net income		0.27		0.24		0.30			0.10
Diluted income (loss) per share(1):
Continuing operations		0.27		0.23		0.30			0.10
Discontinued operations		0.00		0.00		(0.00	)		(0.00	)
Net income		0.27		0.23		0.30			0.10

Fiscal 2014
Total revenue	$	13,883	$	13,604	$	14,616		$	15,336
Operating income from continuing operations		4,329		3,480		5,333			5,434
Income from continuing operations		3,630		2,459		3,674			2,444
Loss from discontinued operations		—		—		(76	)		(100	)
Net income		3,630		2,459		3,598			2,344
Basic income (loss) per share(1):
Continuing operations		0.26		0.18		0.27			0.18
Discontinued operations		0.00		0.00		(0.01	)		(0.01	)
Net income		0.26		0.18		0.26			0.17
Diluted income (loss) per share(1):
Continuing operations		0.26		0.18		0.27			0.18
Discontinued operations		0.00		0.00		(0.01	)		(0.01	)
Net income		0.26		0.18		0.26			0.17

(1)	The sum of the quarterly income (loss) per share amounts may not equal the annual income (loss) per share total because of changes in the weighted average number of shares outstanding that occurred during the year.

Schedule of Valuation and Qualifying Accounts - Valuation and Qualifying Accounts (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Allowance for doubtful accounts [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period	$ 42	$ 26	$ 40
Additions Charged (Credited) to Expenses		24	(11)
Deductions From Reserves	32	8	3
Balance at End of Period	$ 10	42	26
Restructuring accrual [Member]
Valuation And Qualifying Accounts Disclosure [Line Items]
Balance at Beginning of Period		416	192
Additions Charged (Credited) to Expenses			476
Deductions From Reserves		$ 416	252
Balance at End of Period			$ 416

Summary of Significant Accounting Policies and Select Balance Sheet Information - Additional Information (Detail) - USD ($) shares in Millions	3 Months Ended							12 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2013	Mar. 31, 2013	Dec. 31, 2012	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2010	Sep. 30, 2006	Nov. 10, 2015
Summary Of Significant Accounting Policies [Line Items]
Available for sale investments	$ 0		$ 19,863,000					$ 0	$ 19,863,000
Depreciation expense								2,000,000	2,000,000	$ 2,100,000
Gain on sale of investment		$ 500,000		$ 700,000				492,000	842,000	1,430,000
Transfer to Investments								2,000
Revenue recognized from activity with companies in which it had strategic investment										100,000
Amortization expense								800,000	700,000	700,000
Goodwill	8,010,000		8,010,000					8,010,000	8,010,000
Taxes collected from customers and remitted to governmental authorities								100,000	100,000	$ 100,000
Deferred revenue	300,000		300,000					$ 300,000	$ 300,000
Weighted average diluted shares outstanding excluded outstanding stock options								0.5	0.5	0.4
Medtronic [Member] \| Customer Concentration Risk [Member] \| Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Major customer percentage of consolidated revenue								26.00%	19.00%	19.00%
In Vitro Diagnostics [Member]
Summary Of Significant Accounting Policies [Line Items]
Goodwill	8,000,000		8,000,000					$ 8,000,000	$ 8,000,000
Goodwill, impairment charges								0	0	$ 0
Customer Lists [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets, acquired								300,000
Non-compete [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets, acquired								200,000
Other Intangible Assets [Member]
Summary Of Significant Accounting Policies [Line Items]
Intangible assets, acquired								100,000
Nexeon Med Systems Inc
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment					$ 1,000,000			6,500,000			$ 4,100,000
Carrying value of the investment	0		0					0	0
Other Income, Net [Member]
Summary Of Significant Accounting Policies [Line Items]
Gain on sale of investment								500,000
Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Revenue recognized from activity with companies in which it had strategic investment								$ 100,000	100,000
Product sales payment terms								45 days
Maximum [Member] \| Customer Concentration Risk [Member] \| Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Major customer percentage of consolidated revenue								10.00%
Maximum [Member] \| Medtronic [Member] \| Product Concentration Risk [Member] \| Revenue [Member]
Summary Of Significant Accounting Policies [Line Items]
Major customer percentage of consolidated revenue								6.00%
Maximum [Member] \| Nexeon Med Systems Inc
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment										$ 100,000
Minimum [Member]
Summary Of Significant Accounting Policies [Line Items]
Product sales payment terms								30 days
CeloNova BioSciences, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment	$ 1,500,000							$ 1,500,000
CeloNova BioSciences, Inc. [Member] \| Subsequent Event [Member]
Summary Of Significant Accounting Policies [Line Items]
Gross value of business acquired													$ 70,000,000
CeloNova BioSciences, Inc. [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Company's ownership percentage	2.00%							2.00%
ThermopeutiX, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment			$ 1,200,000					$ 1,200,000
ThermopeutiX, Inc. [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Company's ownership percentage	20.00%							20.00%
ViaCyte, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment						$ 100,000		$ 5,300,000				$ 4,700,000
Cost method of investment	$ 500,000							$ 500,000
ViaCyte, Inc. [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Company's ownership percentage	1.00%							1.00%
Vessix Vascular, Inc. [Member]
Summary Of Significant Accounting Policies [Line Items]
Impairment loss on investment								$ 2,500,000			$ 2,400,000
Gain on sale of investment							$ 1,200,000
Vessix Vascular, Inc. [Member] \| Clinical milestone [Member]
Summary Of Significant Accounting Policies [Line Items]
Milestone payment to be received									$ 700,000
Vessix Vascular, Inc. [Member] \| Maximum [Member]
Summary Of Significant Accounting Policies [Line Items]
Potential proceeds on achievement of future milestones	$ 3,300,000							$ 3,300,000

Summary of Significant Accounting Policies and Select Balance Sheet Information - Amortized Cost, Unrealized Holding Gains (Losses) and Fair Value of Available-for-Sale Securities (Details) - USD ($)	Sep. 30, 2015	Sep. 30, 2014
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		$ 18,347,000
Unrealized Gains		1,617,000
Unrealized Losses		(101,000)
Fair Value	$ 0	19,863,000
Municipal bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		1,173,000
Unrealized Gains		5,000
Unrealized Losses		(3,000)
Fair Value		1,175,000
Corporate bonds [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		1,829,000
Unrealized Gains		6,000
Unrealized Losses		(5,000)
Fair Value		1,830,000
U.S. government and government agency obligations [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		7,397,000
Unrealized Gains		12,000
Unrealized Losses		(15,000)
Fair Value		7,394,000
Mortgage-backed securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		5,576,000
Unrealized Gains		43,000
Unrealized Losses		(74,000)
Fair Value		5,545,000
Asset-backed securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		2,370,000
Unrealized Gains		3,000
Unrealized Losses		(4,000)
Fair Value		2,369,000
Equity securities [Member]
Schedule of Available-for-sale Securities [Line Items]
Amortized Cost		2,000
Unrealized Gains		1,548,000
Fair Value		$ 1,550,000

Summary of Significant Accounting Policies and Select Balance Sheet Information - Sales of Available-for-Sale Securities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Investments Debt And Equity Securities [Abstract]
Proceeds from sales	$ 22,199	$ 162,673	$ 44,853
Gross realized gains	548	134	179
Gross realized losses	$ (73)	$ (1)	$ (43)

Summary of Significant Accounting Policies and Select Balance Sheet Information - Components of Inventories (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Inventory Disclosure [Abstract]
Raw materials	$ 1,264	$ 1,056
Finished products	1,715	1,761
Total	$ 2,979	$ 2,817

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Property, Plant and Equipment (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Property, Plant and Equipment [Line Items]
Less accumulated depreciation	$ (25,417)	$ (24,416)
Property and equipment, net	12,968	13,133
Land [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	4,359	4,359
Laboratory Fixtures and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 12,941	12,858
Laboratory Fixtures and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	3 years
Laboratory Fixtures and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	10 years
Building and Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 16,444	16,114
Building and Improvements [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	3 years
Building and Improvements [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	20 years
Office Furniture and Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 3,473	3,060
Office Furniture and Equipment [Member] \| Minimum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	3 years
Office Furniture and Equipment [Member] \| Maximum [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Useful Life	10 years
Construction in Progress [Member]
Property, Plant and Equipment [Line Items]
Property and Equipment, Gross	$ 1,168	$ 1,158

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Other Assets Consist Principally of Strategic Investments (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Schedule of Investments [Line Items]
Other assets, net	$ 479	$ 1,979
CeloNova BioSciences, Inc. [Member]
Schedule of Investments [Line Items]
Other assets, net		1,500
ViaCyte, Inc. [Member]
Schedule of Investments [Line Items]
Other assets, net	$ 479	$ 479

Summary of Significant Accounting Policies and Select Balance Sheet Information - Schedule of Intangible Assets (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Intangible Assets [Line Items]
Definite-lived intangible assets, Accumulated Amortization	$ (6,033)	$ (5,277)
Intangible assets, Gross Carrying Amount	8,793	8,223
Intangible assets, Net	$ 2,760	$ 2,946
Customer Lists [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	9 years	9 years
Definite-lived intangible assets, Gross Carrying Amount	$ 5,132	$ 4,857
Definite-lived intangible assets, Accumulated Amortization	(4,363)	(3,813)
Definite-lived intangible assets, Net	$ 769	$ 1,044
Core Technology [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	8 years	8 years
Definite-lived intangible assets, Gross Carrying Amount	$ 530	$ 530
Definite-lived intangible assets, Accumulated Amortization	(530)	(475)
Definite-lived intangible assets, Net	$ 0	$ 55
Non-compete [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	5 years
Definite-lived intangible assets, Gross Carrying Amount	$ 230
Definite-lived intangible assets, Accumulated Amortization	(12)
Definite-lived intangible assets, Net	$ 218
Patents and Other [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Weighted Average Original Life (Years)	16 years 9 months 18 days	16 years 9 months 18 days
Definite-lived intangible assets, Gross Carrying Amount	$ 2,321	$ 2,256
Definite-lived intangible assets, Accumulated Amortization	(1,128)	(989)
Definite-lived intangible assets, Net	1,193	1,267
Definite-Lived Intangible Assets [Member]
Intangible Assets [Line Items]
Definite-lived intangible assets, Gross Carrying Amount	8,213	7,643
Definite-lived intangible assets, Accumulated Amortization	(6,033)	(5,277)
Definite-lived intangible assets, Net	2,180	2,366
Trademarks [Member]
Intangible Assets [Line Items]
Indefinite-lived intangible assets, Net	$ 580	$ 580

Summary of Significant Accounting Policies and Select Balance Sheet Information - Estimated Amortization Expense (Detail) $ in Thousands	Sep. 30, 2015 USD ($)
Goodwill And Intangible Assets Disclosure [Abstract]
2016	$ 690
2017	279
2018	233
2019	233
2020	$ 221

Summary of Significant Accounting Policies and Select Balance Sheet Information - Denominator for Computation of Basic and Diluted Income Per Share (Detail) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended								12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Earnings Per Share [Abstract]
Net income from continuing operations available to common shareholders	$ 1,358	$ 3,924	$ 3,051	$ 3,614	$ 2,444	$ 3,674	$ 2,459	$ 3,630	$ 11,947	$ 12,207	$ 14,579
Basic weighted average shares outstanding									13,029	13,632	14,464
Dilutive effect of outstanding stock options, non-vested restricted stock, restricted stock units and performance shares									260	244	267
Diluted weighted average shares outstanding									13,289	13,876	14,731

Discontinued Operations - Additional Information (Detail) - USD ($)		1 Months Ended		3 Months Ended	6 Months Ended	12 Months Ended
	Nov. 17, 2011	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2015	Jun. 30, 2013	Sep. 30, 2015	Sep. 30, 2013
Discontinued Operations [Line Items]
Total consideration received from the Pharma Sale	$ 30,000,000
Restricted time period For competition	5 years
Additional litigation expense within discontinued operations		$ 100,000	$ 300,000	$ 2,500,000		$ 2,500,000
Government Authorities in Alabama [Member]
Discontinued Operations [Line Items]
Payment on settlement of retained liability					$ 325,000
Gain (Loss) on sale of discontinued operations, net of income taxes							$ 1,300,000

Discontinued Operations - Operating Results from Discontinued Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Discontinued Operations And Disposal Groups [Abstract]
(Loss) income from discontinued operations	$ (260)	$ 1,136
Income tax benefit (provision)	84	(548)
(Loss) income from discontinued operations, net of income taxes	$ (176)	$ 588
Income tax benefit			$ (600)

- Definition

Amount before tax of income (loss) from a discontinued operation. Includes, but is not limited to, the income (loss) from operations during the phase-out period, gain (loss) on disposal, gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and adjustments to a prior period gain (loss) on disposal.

+ References + Details

- Definition

Amount of tax expense (benefit) related to a discontinued operation. Includes, but is not limited to, tax expense (benefit) related to income (loss) from operations during the phase-out period, tax expense (benefit) related to gain (loss) on disposal, tax expense (benefit) related to gain (loss) for reversal of write-down (write-down) to fair value, less cost to sell, and tax expense (benefit) related to adjustments of a prior period gain (loss) on disposal.

+ References + Details

Fair Value Measurements - Additional Information (Detail) - USD ($)	3 Months Ended				12 Months Ended
	Sep. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Dec. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Gain on sale of investment		$ 500,000		$ 700,000	$ 492,000	$ 842,000	$ 1,430,000
Level 3 assets	$ 0		$ 0		0	$ 0
Level 3 activity					0
CeloNova BioSciences, Inc. [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Impairment loss on investment	$ 1,500,000				1,500,000
ThermopeutiX, Inc. [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Impairment loss on investment			$ 1,200,000		$ 1,200,000

Stockholders' Equity - Additional Information (Detail) - USD ($)					12 Months Ended
	Jul. 08, 2015	Nov. 11, 2014	Sep. 30, 2013	Jun. 30, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013	Nov. 06, 2015	Nov. 05, 2014	Jul. 29, 2013	Jan. 28, 2013
Stockholders Equity [Line Items]
Common stock repurchased					$ 20,000,000	$ 11,541,000	$ 18,809,000
Number of cumulative shares repurchased				405,290
Stock repurchased average price per share				$ 25.47		$ 23.77
Common stock repurchased, Shares						485,777	795,643
Subsequent Event [Member]
Stockholders Equity [Line Items]
Stock repurchase program authorized amount								$ 20,000,000
Remaining amount available for repurchases of shares								$ 30,000,000
January 2013 authorization plan [Member]
Stockholders Equity [Line Items]
Stock repurchase program authorized amount											$ 10,000,000
Previous authorization plan [Member]
Stockholders Equity [Line Items]
Common stock repurchased				$ 300,000
July 2013 authorization plan [Member]
Stockholders Equity [Line Items]
Stock repurchase program authorized amount										$ 20,000,000
Stock repurchased average price per share			$ 21.71
Amount available for repurchases of shares			$ 11,500,000				$ 11,500,000
Common stock repurchased, Shares			390,353
Open Market Share Repurchase Program [Member]
Stockholders Equity [Line Items]
Common stock repurchased							$ 1,000,000
Accelerated Share Repurchase Program [Member]
Stockholders Equity [Line Items]
Stock repurchase program authorized amount									$ 30,000,000
Common stock repurchased, Shares	89,721	758,143
Remaining amount available for repurchases of shares									$ 10,000,000
Accelerated Share Repurchase Program [Member] \| Investment Bank [Member]
Stockholders Equity [Line Items]
Stock repurchased average price per share		$ 23.59
Common stock repurchased, Shares		847,864
Payments for repurchase of common stock		$ 20,000,000
Fair value of common stock		16,000,000
Reduction in common stock		100,000
Reduction in additional paid-in capital		(2,500,000)
Reduction in retained earnings		13,500,000
Initial payment to bank reported as reduction in retained earnings		$ 4,000,000

Stock-Based Compensation Plans - Stock-based Compensation Expenses (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 2,381	$ 3,337	$ 2,552
Product costs [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	24	16	22
Research and development [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	226	175	180
Selling, general and administrative [Member]
Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Line Items]
Total stock-based compensation expense	$ 2,131	$ 3,146	$ 2,350

Stock-Based Compensation Plans - Additional Information (Detail) - USD ($)	3 Months Ended		12 Months Ended
	Dec. 31, 2015	Mar. 31, 2014	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013	Sep. 30, 2012
Stock-Based Compensation Activity [Line Items]
Unrecognized compensation costs related to non-vested awards			$ 1,900,000
Weighted average period for recognition of compensation costs related to non-vested awards			2 years 1 month 6 days
Performance share awards fully expensed			$ 200,000
Weighted average per share fair value of stock options			$ 7.26	$ 8.72	$ 8.69
Dividend yield			0.00%	0.00%	0.00%
Vesting period			3 years	3 years	3 years	3 years
Stock option exercisable on a pro-rata basis			2 years 4 months 24 days
Aggregate intrinsic value of the option shares outstanding			$ 4,500,000
Aggregate intrinsic value of the option shares exercisable			$ 3,800,000
Remaining contractual life of options outstanding			3 years 2 months 12 days
Total pre-tax intrinsic value of options exercised			$ 1,700,000	$ 1,400,000
Number of stock options outstanding			1,118,008	1,210,619	1,368,984	1,325,438
Number of stock options exercisable			797,045
Restricted stock expense			$ 300,000	$ 200,000	$ 100,000
Expenses recognized related to Performance Shares			500,000	600,000	1,200,000
Stock compensation expenses recognized			$ 2,381,000	$ 3,337,000	$ 2,552,000
Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock compensation expenses recognized		$ 900,000
Discontinued Operations [Member]
Stock-Based Compensation Activity [Line Items]
Number of stock options outstanding			0	0	0
Number of stock options exercisable			0	0	0
Fiscal 2012 (2012 - 2014) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year			2012
Performance period end year			2014
Fiscal 2013 (2013 - 2015) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year			2013
Performance period end year			2015
Maximum Shares			85,506
Fiscal 2013 (2013 - 2015) [Member] \| Scenario, Forecast [Member]
Stock-Based Compensation Activity [Line Items]
Maximum Shares	41,727
Fiscal 2014 (2014 - 2016) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year			2014
Performance period end year			2016
Maximum Shares			78,606
Maximum estimated shares earned			3,930
Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Performance period start year			2015
Performance period end year			2017
Maximum Shares			84,398
Maximum estimated shares earned			10,676
Nonqualified Stock Options [Member]
Stock-Based Compensation Activity [Line Items]
Stock option related expense				$ 500,000
Nonqualified Stock Options [Member] \| Granted prior to May 2008 [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period			5 years
Vesting terms			Non-qualified stock options granted prior to May 2008 generally become exercisable with respect to 20% of the shares on each of the first five anniversaries following the grant date
Nonqualified Stock Options [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Vesting terms			The Company modified non-qualified stock option awards granted to Board members in February 2014, which resulted in acceleration of the stock option vesting period. The modification changed the vesting period to a pro-rata basis over a one-year period from a four-year period and resulted in an increase to stock option expense of $0.5 million in fiscal 2014.
Stock option exercisable on a pro-rata basis			1 year	4 years
Nonqualified Stock Options [Member] \| Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period			4 years
Nonqualified Stock Options [Member] \| Employee [Member] \| Granted subsequent to April 2008 [Member]
Stock-Based Compensation Activity [Line Items]
Vesting period			4 years
Vesting terms			Non-qualified stock options granted to the Company’s employees subsequent to April 2008 generally become exercisable with respect to 25% of the shares on each of the first four anniversaries following the grant date
Nonqualified Stock Options [Member] \| Minimum [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service			7 years
Nonqualified Stock Options [Member] \| Maximum [Member] \| Board of Director [Member]
Stock-Based Compensation Activity [Line Items]
Stock option expiration term upon expiration of employment or service			10 years
Restricted Stock [Member]
Stock-Based Compensation Activity [Line Items]
Number of restricted stock awards outstanding			27,775	18,624	5,234	4,000
Number of stock units awarded			18,073	22,155
Number of stock units forfeited			1,316	774	4,000
Restricted Stock [Member] \| Discontinued Operations [Member]
Stock-Based Compensation Activity [Line Items]
Number of restricted stock awards outstanding			0	0	0
Performance Shares [Member] \| Fiscal 2013 (2013 - 2015) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded			$ 900,000
Performance Shares [Member] \| Fiscal 2014 (2014 - 2016) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded			900,000
Performance Shares [Member] \| Fiscal 2015 (2015 - 2017) [Member]
Stock-Based Compensation Activity [Line Items]
Fair value of performance shares for grants awarded			900,000
1999 Employee Stock Purchase Plan [Member]
Stock-Based Compensation Activity [Line Items]
Annual compensation withheld, maximum limit			25,000
Stock compensation expenses recognized			$ 100,000	$ 100,000	$ 100,000
1999 Employee Stock Purchase Plan [Member] \| Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Common stock authorized, shares			400,000
Annual compensation withheld			10.00%
Employee contributions			$ 100,000	100,000
Vesting Anniversary [Member] \| Nonqualified Stock Options [Member] \| Granted prior to May 2008 [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage			20.00%
Vesting Anniversary [Member] \| Nonqualified Stock Options [Member] \| Employee [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage			25.00%
Vesting Anniversary [Member] \| Nonqualified Stock Options [Member] \| Employee [Member] \| Granted subsequent to April 2008 [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage			25.00%
Performance Level [Member] \| Minimum [Member]
Stock-Based Compensation Activity [Line Items]
Vesting percentage			20.00%
Performance Level [Member] \| Maximum [Member]
Stock-Based Compensation Activity [Line Items]
Performance share awards, estimated vesting percentage			200.00%
2009 Equity Incentive Plan [Member]
Stock-Based Compensation Activity [Line Items]
Number of authorized shares in 2009 plan			1,500,000
Number of shares available for future awards			938,391
Stock compensation expenses recognized			$ 100,000	100,000
2009 Equity Incentive Plan [Member] \| Restricted Stock Units (RSUs) [Member]
Stock-Based Compensation Activity [Line Items]
Restricted stock expense				200,000
Stock compensation expenses recognized			$ 200,000	$ 400,000	$ 100,000
Number of stock units awarded			23,736	23,736
Number of stock units forfeited			3,068
2009 Equity Incentive Plan [Member] \| Deferred Stock Units [Member] \| Director [Member]
Stock-Based Compensation Activity [Line Items]
Number of stock units awarded			18,934
Number of deferred stock units issued fair value			$ 400,000

Stock-Based Compensation Plans - Assumptions Used in Stock Option Plans (Detail)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Risk-free interest rates	1.43%	1.19%	0.60%
Expected life	4 years 6 months	4 years 7 months 6 days	4 years 9 months 18 days
Expected volatility	43.00%	45.00%	49.00%
Dividend yield	0.00%	0.00%	0.00%

Stock-Based Compensation Plans - Schedule of Stock Option Activity (Detail) - $ / shares	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Number of Shares Outstanding, Beginning balance	1,210,619	1,368,984	1,325,438
Number of Shares, Granted	164,401	138,837	178,924
Number of Shares, Exercised	(166,422)	(190,434)	(10,273)
Number of Shares, Forfeited	(90,590)	(106,768)	(125,105)
Number of Shares Outstanding, Ending balance	1,118,008	1,210,619	1,368,984
Number of Shares, Exercisable	797,045
Weighted Average Exercise Price, Beginning Balance	$ 20.35	$ 20.13	$ 21.25
Weighted Average Exercise Price, Granted	21.24	22.71	20.85
Weighted Average Exercise Price, Exercised	14.54	14.42	14.40
Weighted Average Exercise Price, Forfeited	35.35	31.26	33.47
Weighted Average Exercise Price, Ending balance	20.10	$ 20.35	$ 20.13
Weighted Average Exercise Price, Exercisable	$ 20.04

Stock-Based Compensation Plans - Schedule of Restricted Stock Awards Activity (Detail) - Restricted Stock [Member] - $ / shares	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares, Beginning balance	18,624	5,234	4,000
Number of Shares, Granted	18,073	22,155
Number of Shares, Vested	(7,606)	(7,991)	5,234
Number of Shares, Forfeited	(1,316)	(774)	(4,000)
Number of Shares, Ending balance	27,775	18,624	5,234
Weighted Average Grant Price, Beginning balance	$ 22.45	$ 23.88	$ 22.11
Weighted Average Grant Price, Granted	21.84	22.67
Weighted Average Grant Price, Vested	22.28	23.98	23.88
Weighted Average Grant Price, Forfeited	22.16	22.58	22.11
Weighted Average Grant Price, Ending balance	$ 22.12	$ 22.45	$ 23.88

Stock-Based Compensation Plans - Schedule of Fair Value at the Date of Grant (Detail)	12 Months Ended
	Sep. 30, 2015 shares
Fiscal 2013 (2013 - 2015) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	8,551
Target Shares	42,753
Maximum Shares	85,506
Fiscal 2014 (2014 - 2016) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	7,861
Target Shares	39,303
Maximum Shares	78,606
Fiscal 2015 (2015 - 2017) [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Minimum Shares	8,440
Target Shares	42,199
Maximum Shares	84,398

Restructuring Charges - Additional Information (Detail) - USD ($)	3 Months Ended	12 Months Ended
	Sep. 30, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Restructuring And Related Activities [Abstract]
Restructuring charges		$ 0	$ 0	$ 476,000
Percentage of eliminated work force				6.00%
Pre-Tax restructuring charges	$ 500,000

Restructuring Charges - Restructuring Accrual Activities (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Restructuring Cost and Reserve [Line Items]
Beginning Balance	$ 416	$ 192
Accrual/(reversal) during the year	(22)	476
Cash payments	(394)	(252)
Ending Balance		416
Employee Severance and Benefits [Member]
Restructuring Cost and Reserve [Line Items]
Beginning Balance	399	10
Accrual/(reversal) during the year	(20)	534
Cash payments	(379)	(145)
Ending Balance		399
Facility-Related Costs [Member]
Restructuring Cost and Reserve [Line Items]
Beginning Balance	17	182
Accrual/(reversal) during the year	(2)	(58)
Cash payments	$ (15)	(107)
Ending Balance		$ 17

Revolving Credit Facility - Additional Information (Detail) - USD ($)	Nov. 04, 2013	Nov. 20, 2015	Sep. 30, 2015
Line of Credit Facility [Line Items]
Credit facility initiation date	Nov. 04, 2013
Revolving credit facility amount	$ 20,000,000
Credit facility fee percentage	0.20%
Line of Credit Facility, Expiration Period	3 years
Debt outstanding			$ 0
Subsequent Event [Member] \| Stock Repurchase Plan [Member]
Line of Credit Facility [Line Items]
Revolving credit facility amount		$ 30,000,000
Minimum [Member]
Line of Credit Facility [Line Items]
Credit facility interest rate	1.375%
Maximum [Member]
Line of Credit Facility [Line Items]
Credit facility interest rate	2.00%

Income Taxes - Schedule of Income Taxes from Continuing Operations (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Current provision:
Federal	$ 6,065	$ 6,470	$ 6,048
State and foreign	136	147	225
Total current provision	6,201	6,617	6,273
Deferred provision (benefit):
Federal	58	(347)	(552)
State	35	(5)	60
Total deferred provision (benefit)	93	(352)	(492)
Income tax provision	$ 6,294	$ 6,265	$ 5,781

Income Taxes - Additional Information (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013	Dec. 31, 2012	Sep. 30, 2012
Income Tax Disclosure [Abstract]
U.S. federal statutory tax rate	35.00%	35.00%	35.00%
Discrete tax benefit				$ 200
Income tax expense (benefit) from discontinued operations		$ (100)	$ 500		$ 1,100
Income tax benefit from sale of discontinued operations					$ 600
Deferred tax asset valuation allowance	$ 5,721	4,836
Unrecognized tax benefits excluding interest and penalties that would impact effective tax rate	900	900	1,000
Liability for unrecognized tax benefits to change significantly in the next 12 months	$ 600	$ 600	$ 700

Income Taxes - Schedule of Reconciliation Difference of Income Taxes (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Amount at statutory U.S. federal income tax rate	$ 6,385	$ 6,465	$ 7,126
Change because of the following items:
State income taxes, net of federal benefit	67	118	278
Stock-based compensation	16	21	25
Valuation allowance change	348	120	(699)
Tax reserve change	34	(121)	(128)
Federal manufacturing deduction	(268)	(235)	(266)
Federal research and development credit	(74)	(67)	(324)
Other	(214)	(36)	(231)
Income tax provision	$ 6,294	$ 6,265	$ 5,781

Income Taxes - Schedule of Deferred Income Taxes (Detail) - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Income Tax Disclosure [Abstract]
Depreciable assets	$ 1,618	$ 1,612
Deferred revenue	96	101
Accruals and reserves	145	324
Stock-based compensation	4,194	4,373
Impaired strategic investments	4,186	3,674
Unrealized gains on investments		(550)
Capital loss carryforward	1,456	1,650
Other	1,276	764
Valuation allowance	(5,721)	(4,836)
Total deferred tax assets	7,250	7,112
Less current deferred tax assets	(546)	(394)
Noncurrent deferred tax assets	$ 6,704	$ 6,718

Income Taxes - Summary of Reconciliation of Unrecognized Tax Benefits (Detail) - USD ($) $ in Thousands	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Income Tax Disclosure [Abstract]
Beginning of fiscal year	$ 1,216	$ 1,300	$ 1,435
Increases in tax positions for prior years	50	43	27
Decreases in tax positions for prior years	(10)	(1)	(278)
Increases in tax positions for current year	146	149	122
Lapse of the statute of limitations	(154)	(275)	(6)
End of fiscal year	$ 1,248	$ 1,216	$ 1,300

Defined Contribution Plan - Additional Information (Detail) - USD ($) $ in Millions	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Compensation And Retirement Disclosure [Abstract]
Percentage of employee contributions	50.00%
Percentage of employee eligible compensation	6.00%
Contribution expense	$ 0.3	$ 0.2	$ 0.2

Amounts Reclassified Out of Accumulated Other Comprehensive Income - Additional Information (Detail) - USD ($)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014
Accumulated Other Comprehensive Income Pre-Tax [Member] \| Maximum [Member]
Accumulated Other Comprehensive Income Loss [Line Items]
Amounts reclassified out of AOCI pre-tax basis	$ 300,000	$ 100,000

Commitments and Contingencies - Additional Information (Detail)	1 Months Ended	3 Months Ended		6 Months Ended	9 Months Ended	12 Months Ended
	Sep. 30, 2014 USD ($)	Sep. 30, 2015 USD ($) € / $	Sep. 30, 2014 USD ($)	Mar. 31, 2015 USD ($)	Jun. 30, 2015 USD ($)	Sep. 30, 2015 USD ($) € / $	Sep. 30, 2015 EUR (€)	Sep. 30, 2013 USD ($)	Sep. 29, 2015 USD ($)
Commitments And Contingencies [Line Items]
Agreed to pay the customer and settlement of claim									$ 2,500,000
Undisputed royalties earned									$ 500,000
Revenue recognized by company		$ 500,000
Pre tax compensation expense		$ 2,500,000
License agreement commencement date						2006-03	2006-03
Annual minimum payments for licenses						$ 223,000	€ 200,000
Exchange rate relating to license payment \| € / $		1.11707				1.11707
Future minimum payments associated with license	$ 2,700,000		$ 2,700,000
Additional maximum amount payable on successful achievement of specified milestones to sellers of PR Pharma		$ 2,500,000				$ 2,500,000
Indemnification period						5 years	5 years
Rent expense related to operating leases	$ 100,000					$ 100,000		$ 100,000
Maximum [Member]
Commitments And Contingencies [Line Items]
Rights to receive contingent consideration			$ 100,000
Patents [Member]
Commitments And Contingencies [Line Items]
Patent expiry date						2027-09	2027-09
January 2009 through September 2014 [Member]
Commitments And Contingencies [Line Items]
Royalties overpaid				$ 5,700,000	$ 5,700,000

Commitments and Contingencies - Summary of Annual Commitments Pursuant to Operating Lease Agreements (Detail) $ in Thousands	Sep. 30, 2015 USD ($)
Commitments And Contingencies Disclosure [Abstract]
2016	$ 73
2017	68
2018	70
2019	72
2020	74
Thereafter	12
Total minimum lease payments	$ 369

Operating Segment Information - Additional Information (Detail)	3 Months Ended	12 Months Ended
	Mar. 31, 2014 USD ($)	Sep. 30, 2015 USD ($) Segment Source	Sep. 30, 2014 USD ($)	Sep. 30, 2013 USD ($)
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Number of operating segments \| Segment		2
Allocated share-based compensation expense		$ 2,381,000	$ 3,337,000	$ 2,552,000
Restructuring charges		$ 0	0	476,000
Number of primary sources of revenue \| Source		2
SRI Litigation [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Legal expenses				1,000,000
Director [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Allocated share-based compensation expense	$ 900,000
Corporate [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Restructuring charges				$ 500,000
Corporate [Member] \| Director [Member]
Segment Reporting, Reconciling Item for Operating Profit (Loss) from Segment to Consolidated [Line Items]
Allocated share-based compensation expense			$ 900,000

Operating Segment Information - Segment Revenue, Operating Income and Depreciation and Amortization (Detail) - USD ($) $ in Thousands	3 Months Ended								12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Segment Reporting Information [Line Items]
Total revenue	$ 17,364	$ 15,914	$ 14,415	$ 14,205	$ 15,336	$ 14,616	$ 13,604	$ 13,883	$ 61,898	$ 57,439	$ 56,132
Operating income	$ 4,266	$ 5,857	$ 3,932	$ 5,034	$ 5,434	$ 5,333	$ 3,480	$ 4,329	19,089	18,576	18,820
Depreciation and amortization									2,805	2,715	2,886
Operating Segments [Member]
Segment Reporting Information [Line Items]
Operating income									25,676	26,095	25,386
Operating Segments [Member] \| Medical Device [Member]
Segment Reporting Information [Line Items]
Total revenue									45,944	43,068	41,153
Operating income									21,192	22,636	21,164
Depreciation and amortization									1,138	1,136	1,255
Operating Segments [Member] \| In Vitro Diagnostics [Member]
Segment Reporting Information [Line Items]
Total revenue									15,954	14,371	14,979
Operating income									4,484	3,459	4,222
Depreciation and amortization									873	850	864
Corporate [Member]
Segment Reporting Information [Line Items]
Operating income									(6,587)	(7,519)	(6,566)
Depreciation and amortization									$ 794	$ 729	$ 767

Operating Segment Information - Revenue from Major Customers (Detail)	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Revenue [Member] \| Customer Concentration Risk [Member] \| Medtronic [Member]
Revenue, Major Customer [Line Items]
Percentage of revenue	26.00%	19.00%	19.00%

Operating Segment Information - Geographic Revenue (Detail) - Revenue [Member] - Geographic Concentration Risk [Member]	12 Months Ended
	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Domestic [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Percentage of revenue	77.00%	78.00%	79.00%
Foreign [Member]
Revenues from External Customers and Long-Lived Assets [Line Items]
Percentage of revenue	23.00%	22.00%	21.00%

Subsequent Events - Additional Information (Detail) € in Millions			12 Months Ended
	Nov. 20, 2015 USD ($)	Nov. 20, 2015 EUR (€)	Sep. 30, 2015 USD ($)	Nov. 20, 2015 EUR (€)	Nov. 06, 2015 USD ($)
Subsequent Event [Line Items]
Upfront payments			$ 270,000
Subsequent Event [Member]
Subsequent Event [Line Items]
Stock repurchase program authorized amount					$ 20,000,000
Remaining amount available for repurchases of shares					$ 30,000,000
Subsequent Event [Member] \| Stock Repurchase Plan [Member]
Subsequent Event [Line Items]
Increase in revolving credit facility capacity	$ 20,000,000
Subsequent Event [Member] \| Creagh [Member]
Subsequent Event [Line Items]
Outstanding common shares and voting shares percentage	100.00%			100.00%
Upfront payments	$ 19,300,000	€ 18
Contingent milestone payments	12,800,000			€ 12
Subsequent Event [Member] \| Creagh [Member] \| Maximum [Member]
Subsequent Event [Line Items]
Payments to acquire business	$ 32,100,000	€ 30

Quarterly Financial Data (Unaudited) - Summary of Unaudited Quarterly Results (Detail) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended								12 Months Ended
	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2014	Sep. 30, 2014	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Quarterly Financial Information Disclosure [Abstract]
Total revenue	$ 17,364	$ 15,914	$ 14,415	$ 14,205	$ 15,336	$ 14,616	$ 13,604	$ 13,883	$ 61,898	$ 57,439	$ 56,132
Operating income from continuing operations	4,266	5,857	3,932	5,034	5,434	5,333	3,480	4,329	19,089	18,576	18,820
Income from continuing operations	1,358	3,924	3,051	3,614	2,444	3,674	2,459	3,630	11,947	12,207	14,579
Loss from discontinued operations					(100)	(76)				(176)	588
Net income	$ 1,358	$ 3,924	$ 3,051	$ 3,614	$ 2,344	$ 3,598	$ 2,459	$ 3,630	$ 11,947	$ 12,031	$ 15,167
Basic income (loss) per share:
Continuing operations	$ 0.10	$ 0.30	$ 0.24	$ 0.27	$ 0.18	$ 0.27	$ 0.18	$ 0.26	$ 0.92	$ 0.90	$ 1.01
Discontinued operations	0.00	0.00	0.00	0.00	(0.01)	(0.01)	0.00	0.00	0.00	(0.01)	0.04
Net income	0.10	0.30	0.24	0.27	0.17	0.26	0.18	0.26	0.92	0.88	1.05
Diluted income (loss) per share:
Continuing operations	0.10	0.30	0.23	0.27	0.18	0.27	0.18	0.26	0.90	0.88	0.99
Discontinued operations	0.00	0.00	0.00	0.00	(0.01)	(0.01)	0.00	0.00	0.00	(0.01)	0.04
Net income	$ 0.10	$ 0.30	$ 0.23	$ 0.27	$ 0.17	$ 0.26	$ 0.18	$ 0.26	$ 0.90	$ 0.87	$ 1.03

Quarterly Financial Data (Unaudited) - Additional Information (Detail) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended						12 Months Ended
	Sep. 30, 2014	Jun. 30, 2014	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Sep. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2015	Sep. 30, 2014	Sep. 30, 2013
Quarterly Financial Data [Line Items]
Gain on sale of strategic investment					$ 500			$ 700	$ 492	$ 842	$ 1,430
Royalty payment				$ 600
Claim settlement	$ 100	$ 300	$ 2,500						2,500
Impairment losses on strategic investments			1,500			$ 1,200			1,500	1,184	158
Contingent royalties			$ 800
Allocated share-based compensation expense									$ 2,381	$ 3,337	$ 2,552
Director [Member]
Quarterly Financial Data [Line Items]
Allocated share-based compensation expense							$ 900

Fair Value Measurements - Assets and Liabilities Measured at Fair Value on Recurring Basis (Detail) - Assets and Liabilities Measured at Fair Value on a Recurring Basis [Member] - USD ($) $ in Thousands	Sep. 30, 2015	Sep. 30, 2014
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	$ 53,591	$ 59,963
U.S. government and government agency obligations [Member] \| Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		7,394
Mortgage-backed securities [Member] \| Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		5,545
Asset-backed securities [Member] \| Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		2,369
Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	53,591	40,100
Available-for-sale equity securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		1,550
Municipal bonds [Member] \| Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		1,175
Corporate bonds [Member] \| Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		1,830
Quoted Prices in Active Markets for Identical Instruments (Level 1) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		1,550
Quoted Prices in Active Markets for Identical Instruments (Level 1) [Member] \| Available-for-sale equity securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		1,550
Significant Other Observable Inputs (Level 2) [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	53,591	58,413
Significant Other Observable Inputs (Level 2) [Member] \| U.S. government and government agency obligations [Member] \| Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		7,394
Significant Other Observable Inputs (Level 2) [Member] \| Mortgage-backed securities [Member] \| Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		5,545
Significant Other Observable Inputs (Level 2) [Member] \| Asset-backed securities [Member] \| Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		2,369
Significant Other Observable Inputs (Level 2) [Member] \| Cash equivalents [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value	$ 53,591	40,100
Significant Other Observable Inputs (Level 2) [Member] \| Municipal bonds [Member] \| Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		1,175
Significant Other Observable Inputs (Level 2) [Member] \| Corporate bonds [Member] \| Available-for-sale debt securities [Member]
Fair Value, Assets and Liabilities Measured on Recurring Basis [Line Items]
Total assets measured at fair value		$ 1,830